var title_f23_23_23920="SLS MRI 16 years";
var content_f23_23_23920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F61461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F61461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Brain MRI of a 16 year old with Sjogren-Larsson syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 187px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T2-weighted MR images (3100/98 [TR/TE]). Images A and B) Severe signal-intensity changes of the periventricular white matter with predominant involvement of the frontal trigones. Image C) Small areas of unmyelinated subcortical association fibers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Willemsen, MA, Van Der, Graaf M, Van Der, Knaap MS, et al. MR imaging and proton MR spectroscopic studies in Sjogren-Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am J Neuroradiol 2004; 25:649. Copyright &copy;2004 American Society of Neuroradiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_23_23920=[""].join("\n");
var outline_f23_23_23920=null;
var title_f23_23_23921="Patient information: Hypospadias (The Basics)";
var content_f23_23_23921=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/84041\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/6/42082\">",
"         Hypospadias",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?42/58/43936\">",
"         Patient information: Undescended testes (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hypospadias (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hypospadias-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H188190871\">",
"      <span class=\"h1\">",
"       What is hypospadias?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hypospadias is the medical term for a type of birth defect that affects the penis. In boys born with this birth defect, the tube that carries urine from the bladder to the outside of the body, called the &ldquo;urethra,&rdquo; does not form normally. As a result, the hole that urine comes out of&mdash;called the &ldquo;urethral opening&rdquo;&mdash;is in the wrong place (",
"      <a class=\"graphic graphic_figure graphicRef83947 \" href=\"UTD.htm?41/6/42082\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      In a normal penis, the urethral opening (the hole) is at the tip of the penis. In a penis with hypospadias the hole can be close to the tip, somewhere along the shaft of the penis, or down by the testicles. If the condition is severe and is not corrected, it can cause urine to flow in an unusual direction. Because of this boys with severe hypospadias that are not corrected have to sit down to urinate.",
"     </p>",
"     <p>",
"      Severe hypospadias can also harm a boy&rsquo;s ability to get a woman pregnant when he grows up. That&rsquo;s because severe hypospadias can affect the erection of the penis and how sperm are delivered into the vagina during sex.",
"     </p>",
"     <p>",
"      Boys born with hypospadias sometimes also have an undescended testicle. That&rsquo;s when 1 of the boy&rsquo;s testicles stays in the belly instead of dropping down into the sac between his legs (called the scrotum).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H188190903\">",
"      <span class=\"h1\">",
"       Will my son need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. If your son has hypospadias, his healthcare team probably found it during the exam they did right after your son was born. Sometimes after finding hypospadias, doctors order blood tests to find out if the cause is a hormone- or gene-related problem. They also sometimes order an imaging test called an ultrasound if they cannot locate the testicles. The ultrasound can show where the testicles are and whether they look normal.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H188190918\">",
"      <span class=\"h1\">",
"       How is hypospadias treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment is not always needed. Boys with mild hypospadias can often urinate normally, although their urine stream might point in a different direction than it does in other boys. Boys with mild hypospadias can usually also have sex normally when they grow up.",
"     </p>",
"     <p>",
"      In boys with more severe hypospadias, the main treatment is surgery to create a new urethra that has an opening in the right place. This surgery is usually done when the boy is about 6 months old. Some boys need more than 1 surgery to repair the hypospadias.",
"     </p>",
"     <p>",
"      In boys who might need surgery, it&rsquo;s a good idea to hold off on circumcision. That way, surgeons can use the skin that would normally be removed during a circumcision to rebuild parts of the penis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H188190933\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/58/43936?source=see_link\">",
"       Patient information: Undescended testes (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/23/23921?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 84041 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-41B8DEA544-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_23_23921=[""].join("\n");
var outline_f23_23_23921=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H188190871\">",
"      What is hypospadias?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H188190903\">",
"      Will my son need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H188190918\">",
"      How is hypospadias treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H188190933\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/84041\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/6/42082\">",
"      Hypospadias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/58/43936?source=related_link\">",
"      Patient information: Undescended testes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_23_23922="Bucket handle fracture";
var content_f23_23_23922=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Bucket handle fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    AP and oblique views of the right ankle. Metaphyseal corner (bucket handle) fracture of the distal aspect of the tibia (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David Mathison, MD and Dewesh Agrawal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_23_23922=[""].join("\n");
var outline_f23_23_23922=null;
var title_f23_23_23923="Ecallantide: Drug information";
var content_f23_23_23923=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ecallantide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/7/34931?source=see_link\">",
"    see \"Ecallantide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9728482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9640246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kalbitor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9644429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Kallikrein Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9728582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Treatment of HAE attacks:",
"     </b>",
"     SubQ: 30 mg (as three 10 mg [1 mL] injections); may repeat an additional 30 mg within 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9728581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;16 years: Refer to adult dosing",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9728583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15822393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15822394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9728587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kalbitor&reg;: 10 mg/mL (1 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9728504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9728483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM192722.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM192722.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9728584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer as 3 (10 mg/mL each) injections subcutaneously into skin of abdomen, upper arm, or thigh (do not administer at site of attack). Recommended needle size is 27 gauge. Separate injections by 2 inches (5 cm). May inject all doses in same or different location; rotation of sites is not necessary. Monitor/observe for hypersensitivity.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9642662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute attacks of hereditary angioedema (HAE)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9728541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (8% to 16%), fatigue (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (5% to 13%), diarrhea (4% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (4% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (5%), rash (3%), urticaria (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Vomiting (6%), upper abdominal pain (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site reactions (3% to 7%; includes bruising, erythema, irritation, pain, pruritus, urticaria)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory infection (8%), nasopharyngitis (3% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Antibody formation (5% to 7%), anaphylaxis (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening) Hypersensitivity (chest discomfort, flushing, pharyngeal edema, rhinorrhea, sneezing, nasal congestion, wheezing, hypotension)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9728509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ecallantide or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9728528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Serious hypersensitivity reactions, including anaphylaxis have been reported; administer only by healthcare provider in presence of appropriate medical support to manage anaphylaxis and hereditary angioedema. Do not administer to patients with known hypersensitivity to ecallantide.",
"     </b>",
"     Reactions usually occur within 1 hour and may include chest discomfort, flushing, hypotension, nasal congestion, pharyngeal edema, pruritus, rash, rhinorrhea, sneezing, throat irritation, urticaria, and wheezing. Signs/symptoms of hypersensitivity reactions may be similar to those associated with hereditary angioedema attacks, therefore, consideration should be given to treatment methods; monitor patients closely.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9922507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9728506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9728507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were noted in animal studies. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefits justify the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9728508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Kalbitor Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (1 mL): $3740.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9728586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for hypersensitivity reaction",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9728559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ecallantide is a recombinant protein which inhibits the conversion of high molecular weight kininogen to bradykinin by selectively and reversibly inhibiting plasma kallikrein. Unregulated bradykinin production is thought to contribute to the increased vascular permeability and angioedema observed in HAE.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9728561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset: 30 minutes to 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: 18.6-34.2 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 1.5-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: ~2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Primarily urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Craig T, Riedl M, Dykewicz MS, et al, &ldquo;When is Prophylaxis for Hereditary Angioedema Necessary?&rdquo;",
"      <i>",
"       Ann Alllergy Ashtma Immunol",
"      </i>",
"      , 2009, 102(5):366-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/23/23923/abstract-text/19492656/pubmed\" id=\"19492656\" target=\"_blank\">",
"        19492656",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Epstein TG and Bernstein JA. &ldquo;Current and Emerging Management Options for Hereditary Angioedema in the US,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2008, 68(18):2561-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/23/23923/abstract-text/19093699/pubmed\" id=\"19093699\" target=\"_blank\">",
"        19093699",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9035 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-76D4E16EBB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_23_23923=[""].join("\n");
var outline_f23_23_23923=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9728482\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9640246\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9644429\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9728582\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9728581\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9728583\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822393\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822394\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9728587\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9728504\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9728483\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9728584\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9642662\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9728541\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9728509\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9728528\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299247\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9922507\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9728506\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9728507\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9728508\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322780\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9728586\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9728559\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9728561\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9035\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9035|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/7/34931?source=related_link\">",
"      Ecallantide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_23_23924="EPT plot of achalasia subtypes in the Chicago Classification";
var content_f23_23_23924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F86439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F86439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Esophageal pressure topography plot of achalasia subtypes in the Chicago Classification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In each case, the 30 mmHg isobaric contour is highlighted in black and there is impaired EGJ relaxation evident by the EGJ never relaxing to less than 30 mmHg in any panel. With type I achalasia, there is minimal contractile activity between the UES and EGJ. Type II is defined by &ge;20 percent of swallows (supine posture, 5 mL water) with panesophageal pressurization to &ge;30 mmHg. With type III, there is &ge;20 percent of swallows with either premature contractions or fragments of peristalsis.",
"    <div class=\"footnotes\">",
"     EGJ: esophagogastric junction; UES: upper esophageal sphincter.",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Pandolfino JE, Kwiatek MA, Nealis T, et al. Achalasia: a new clinically relevant classification by high-resolution manometry. Gastroenterology 2008; 135:1526. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_23_23924=[""].join("\n");
var outline_f23_23_23924=null;
var title_f23_23_23925="Transvenous ICD lead systems";
var content_f23_23_23925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Current pathways for modern transvenous ICD lead systems",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left picture: With the Active Can&reg; electrode, current flows between the right ventricular (RV) electrode and the housing (Active Can) of the pulse generator. Right picture: In a second system, current flows between two transvenous electrodes (RV and superior vena cava) and does not use the housing of the pulse generator as an electrode. These two systems have equivalent efficacy. The Active Can&reg; must be placed in the pectoral region, whereas the pulse generator of the two coil system on the right can be placed in either the pectoral region or the abdomen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_23_23925=[""].join("\n");
var outline_f23_23_23925=null;
var title_f23_23_23926="Primary sclerosing cholangitis - high power";
var content_f23_23_23926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary sclerosing cholangitis (high power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A bile duct with vacuolated epithelial cells at the center of an onion skin lesion. The adjacent arteriole is similarly surrounded by scar tissue. This was a percutaneous biopsy from a 28-year-old graduate student who had PSC and Crohn's colitis. Both diseases were quiescent at the time of the biopsy. Although virtually diagnostic of PSC, onion skin lesions such as these are rarely seen in percutaneous liver biopsies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_23_23926=[""].join("\n");
var outline_f23_23_23926=null;
var title_f23_23_23927="Early detection of epithelial ovarian cancer: Role of symptom recognition";
var content_f23_23_23927=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Early detection of epithelial ovarian cancer: Role of symptom recognition",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/23/23927/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/23/23927/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/23/23927/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/23/23927/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/23/23927/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/23/23927/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/23/23927/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian cancer is the second most common gynecologic malignancy and the most common cause of death among women with gynecologic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/1\">",
"     1",
"    </a>",
"    ]. This poor prognosis is due, in large part, to the fact that most women are diagnosed at an advanced stage, while early stages of the disease are potentially curable. Unfortunately, attempts to develop screening programs for epithelial ovarian cancer using pelvic imaging or tumor markers have not yet been successful. The identification of epithelial ovarian cancer symptoms to aid early detection has become a focus of clinical research.",
"   </p>",
"   <p>",
"    Epithelial carcinoma of the ovaries, fallopian tubes, and peritoneum are clinically similar. Evidence suggests that these diseases have a common pathogenesis, and may be initiated in the fallopian tubes. The term ovarian cancer will be used in this topic to refer to disease of any of these three sites.",
"   </p>",
"   <p>",
"    Early detection of epithelial ovarian cancer through symptoms recognition is reviewed here. Screening and diagnosis of epithelial ovarian cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link\">",
"     \"Screening for ovarian cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8563428\">",
"    <span class=\"h1\">",
"     EVIDENCE REGARDING EARLY SYMPTOMS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8563498\">",
"    <span class=\"h2\">",
"     Presence of early symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, epithelial ovarian cancer was called the \"silent killer\" because symptoms were not thought to occur until very late in the course of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/2\">",
"     2",
"    </a>",
"    ]. Advanced epithelial ovarian cancer typically presents with abdominal distention, nausea, anorexia, or early satiety due to the presence of ascites and omental or bowel metastases; dyspnea is occasionally present due to a pleural effusion. However, studies have found that symptoms occur in many women even at early stages of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/3-8\">",
"     3-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most women with epithelial ovarian cancer have pelvic or abdominal symptoms prior to their diagnosis. This was demonstrated in a meta-analysis that included 21 mostly retrospective studies (one study was prospective) of women with epithelial ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/9\">",
"     9",
"    </a>",
"    ]. The proportion of women report symptoms differed by study design (7 percent were asymptomatic by patient interview or questionnaire; 23 percent according to medical records). This difference is likely due to recall bias in the patient report studies.",
"   </p>",
"   <p>",
"    The symptoms that were most commonly reported by at least half of study subjects were: abdominal",
"    <span class=\"nowrap\">",
"     pain/discomfort",
"    </span>",
"    and abdominal",
"    <span class=\"nowrap\">",
"     swelling/bloating.",
"    </span>",
"    These symptoms may be attributed to many different conditions. It appears, though, that they are more common, recur more frequently, and are more severe in women prior to a diagnosis of epithelial ovarian cancer than in other women.",
"   </p>",
"   <p>",
"    The rate of symptoms in women with epithelial ovarian cancer compared with other women was illustrated in three case control studies included in the meta-analysis. As an example, one study surveyed 128 women with pelvic masses prior to undergoing surgery (44 were ultimately diagnosed with epithelial ovarian cancer) and 1011 of whom presented to a primary care clinic for a problem visit [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/7\">",
"     7",
"    </a>",
"    ]. Women with epithelial ovarian cancer had a significantly higher rate of the following symptoms compared with those with benign masses and with the primary care patients, respectively: increased abdominal size (64 versus 56 and 19 percent); bloating (70 versus 49 and 38 percent); and urinary tract symptoms (particularly urgency) (55 versus 31 and 32 percent). Pelvic pain, abdominal pain, abdominal mass, difficulty eating, and constipation were significantly more common in women with epithelial ovarian cancer than in primary care patients, but not in those with pelvic masses.",
"   </p>",
"   <p>",
"    The pattern and quality of symptoms appears to differ among patient with cancer. In the meta-analysis, compared with primary care patients, symptoms in women with epithelial ovarian cancer recurred more frequently (20 to 30 times versus 2 to 3 times per month), were more severe, and had a shorter duration (less than three to six months versus one year or more) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, epithelial ovarian cancer patients were more likely to have multiple symptoms (a triad of bloating, increased abdominal size, and urinary urgency was present in 44 versus 8 percent).",
"   </p>",
"   <p>",
"    The increased likelihood of symptoms in women with epithelial ovarian cancer was further supported by a study that compared Medicare claims linked to the California Surveillance, Epidemiology and End Results cancer database for 1985 women with epithelial ovarian cancer, 6024 women with breast cancer, and over 10,000 women without cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/10\">",
"     10",
"    </a>",
"    ]. Epithelial ovarian cancer patients were significantly more likely to have health care visits for abdominal swelling and gastrointestinal symptoms in the six months prior to diagnosis than age-matched breast cancer and non-cancer controls.",
"   </p>",
"   <p>",
"    The duration of the onset of symptoms to time of diagnosis of ovarian cancer varies. A study of 1700 women with ovarian cancer reported that 30 percent of women had symptoms for 0 to 2 months, 35 percent for 3 to 6 months, 20 percent for 7 to 12 months, and 15 percent for greater than 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/3\">",
"     3",
"    </a>",
"    ]. Women who felt that they had ignored their symptoms were more frequently found to have advanced stage disease; however, this question may be influenced by recall bias.",
"   </p>",
"   <p>",
"    Use of symptom recognition may have the potential to identify women with early stage disease. Women with early stage epithelial ovarian cancer appear to have symptoms, but less frequently than those with late stage cancer (89 versus 97 percent in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/3\">",
"     3",
"    </a>",
"    ]) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/9\">",
"     9",
"    </a>",
"    ]. Prospective studies are needed to determine whether recognition of epithelial ovarian cancer symptoms results in earlier diagnosis, and ultimately, in improved prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Role of early detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each year approximately 21,990 women in the United States are diagnosed with epithelial ovarian cancer and an estimated 15,460 women die of this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/1\">",
"     1",
"    </a>",
"    ]. The goal of early detection is to reduce epithelial ovarian cancer mortality by diagnosing the disease while it is confined to the ovary, when the five-year survival rate is 80 to 90 percent. Unfortunately, almost 80 percent of women have lymph node or distant metastases at the time of diagnosis; five-year survival rates fall to 19 to 32 percent for advanced disease (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64569 \" href=\"UTD.htm?27/5/27740\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A secondary goal is detection and treatment of advanced disease as early as possible. Cure rates are two-fold for women in whom optimal cytoreduction (less than 1 cm of gross residual disease following surgery) can be achieved compared with those who do not have an optimal surgery (30 to 40 percent cure versus 15 to 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/12\">",
"     12",
"    </a>",
"    ]. The most significant factor associated with optimal cytoreduction is the volume of disease at the time of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link&amp;anchor=H8#H8\">",
"     \"Epithelial ovarian cancer: Initial surgical management\", section on 'Optimal cytoreduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some evidence suggests that evaluation of ovarian cancer symptoms results in identification of more women with completely resectable disease. The highest quality data regarding this are from the pilot phase of the Diagnosing Ovarian Cancer Early (DOvE) study, a prospective study in which 1455 women age 50 or older with symptoms associated with ovarian cancer were evaluated with serum CA 125 and transvaginal ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/14\">",
"     14",
"    </a>",
"    ]. At 7-month follow-up, 239 women (16 percent) had an initial abnormal test result and underwent further evaluation and 11 women (0.8 percent) were diagnosed with invasive ovarian, fallopian tubal, or peritoneal cancers. Only one patient who underwent exploratory surgery was found to have benign rather than malignant disease. Among the women with ovarian, fallopian tubal, or peritoneal cancer, 8 (72 percent) were completely resectable compared with 23 percent in a control group of women with ovarian cancer who presented during the study period to gynecologic oncologists at the same institution.",
"   </p>",
"   <p>",
"    Historically, epithelial ovarian cancer was called the \"silent killer\" because symptoms were not thought to occur until very late in the course of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/2\">",
"     2",
"    </a>",
"    ]. Advanced epithelial ovarian cancer typically presents with abdominal distention, nausea, anorexia, or early satiety due to the presence of ascites and omental or bowel metastases; dyspnea is occasionally present due to a pleural effusion. However, studies have found that symptoms occur in many women even at early stages of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. For this reason, early identification of symptomatic women has become a goal of the current approach to this disease.",
"   </p>",
"   <p>",
"    It is hypothesized that if an association between specific patterns of symptoms and epithelial ovarian cancer can be identified, earlier detection of disease may be possible. At issue is whether diagnosing epithelial ovarian cancer three to six months earlier will improve prognosis. The potential impact of early detection depends upon how much time it takes to progress from disease confined to the ovary or fallopian tube to metastatic disease as well as how quickly metastases increase in volume. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=see_link&amp;anchor=H26443084#H26443084\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\", section on 'Fallopian tubal carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no definitive data regarding the doubling time for ovarian cancer. In one study, the average time to develop port site metastasis after laparoscopy in ovarian cancer was 17 days [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/15\">",
"     15",
"    </a>",
"    ]. A modelling study calculated that ovarian tumors may spend more than four years as stage I or II and one year as stage III or IV until they become clinically apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/16\">",
"     16",
"    </a>",
"    ]. In recurrent ovarian cancer, the median doubling time of CA 125 (a surrogate for volume of disease) is 40 days but the range of doubling times is very wide and prognosis was significantly worse in those with quick doubling times compared with those with long doubling times [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms that are associated with epithelial ovarian cancer are often nongynecologic and, frequently, nonspecific (",
"    <a class=\"graphic graphic_table graphicRef78148 \" href=\"UTD.htm?6/6/6251\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Patients and providers may not consider the possibility of epithelial ovarian cancer when these symptoms arise. Thus, another important clinical challenge is to identify which symptoms warrant further evaluation for epithelial ovarian cancer, without resulting in large-scale unnecessary testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL APPROACH TO SYMPTOM RECOGNITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following discussion reviews our clinical approach to early detection of epithelial ovarian cancer through symptom recognition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk assessment for ovarian cancer depends upon age and family history. It is probably most effective to focus attention on symptoms in women who are at an increased risk (ie, over 40 years old or with a family history of ovarian or related cancer). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=see_link&amp;anchor=H6092142#H6092142\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women may present with symptoms suggestive of epithelial ovarian cancer or such symptoms can be elicited during a routine review of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bloating",
"     </li>",
"     <li>",
"      Urinary urgency or frequency",
"     </li>",
"     <li>",
"      Difficulty eating or feeling full",
"     </li>",
"     <li>",
"      Abdominal or pelvic pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women who complain of these symptoms should be further evaluated with a thorough history to assess for other potential symptoms of epithelial ovarian cancer and to gain additional information about each symptom (eg, frequency, severity). Symptoms that are of new onset, coexist with other symptoms, occur almost daily, and are more severe than expected warrant further evaluation. For example, persistent rather than fluctuating abdominal distension was associated with epithelial ovarian cancer in one small observational study [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A population-based study in the United Kingdom found that a clinical algorithm was able to predict the risk of a diagnosis of ovarian cancer within two years based upon family history of ovarian cancer or a set of symptoms (eg, abdominal distension, abdominal pain) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/19\">",
"     19",
"    </a>",
"    ]. In the two-year study period, 63 percent of the ovarian cancers were diagnosed among the 10 percent of women with the highest predicted risk. The top predictive factors were: abdominal distention, family history of ovarian cancer, postmenopausal bleeding, and appetite loss. This algorithm is not available for clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Symptom index",
"    </span>",
"    &nbsp;&mdash;&nbsp;A symptom index has been developed to aid clinicians in evaluating women for early symptoms of epithelial ovarian cancer. Further validation studies are needed for this index and it is not yet recommended for routine clinical use. The symptom index is considered to be positive if a woman reports any of the following symptoms that are: (1) new to her within the past year and (2) occur more than 12 times per month [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pelvic or abdominal pain",
"     </li>",
"     <li>",
"      Increased abdominal size or abdominal bloating",
"     </li>",
"     <li>",
"      Difficulty eating or feeling full quickly",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Follow-up for a positive index include the standard steps used to evaluate a woman with suspected epithelial ovarian cancer: assessment of risk factors, pelvic imaging, serum CA 125 concentration, and possible referral to a gynecologic oncologist. Decisions regarding surgical exploration should not be made based upon a positive symptom index alone.",
"   </p>",
"   <p>",
"    The initial study to develop the epithelial ovarian cancer symptom index was a case control study in which 149 women with epithelial ovarian cancer, 255 women enrolled in an epithelial ovarian cancer screening program, and 233 women referred for",
"    <span class=\"nowrap\">",
"     pelvic/abdominal",
"    </span>",
"    ultrasound were surveyed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/8\">",
"     8",
"    </a>",
"    ]. The cases and controls were divided randomly into two groups, and in the initial phase of the study, the symptom index was developed by evaluating the cases and controls in one group.",
"    <span class=\"nowrap\">",
"     Pelvic/abdominal",
"    </span>",
"    pain, increased abdominal",
"    <span class=\"nowrap\">",
"     size/bloating,",
"    </span>",
"    and difficulty",
"    <span class=\"nowrap\">",
"     eating/feeling",
"    </span>",
"    full were the symptoms that were most significantly associated with epithelial ovarian cancer when they were present for less than one year and occurred for more than 12 days per month. These results were then used as the reference standard to determine the performance of the index in the other part of sample. By disease stage, sensitivity of the index for early stage was 57 and for late stage was 80 percent. According to patient age, sensitivity and specificity for women &lt;50 years were both 87 percent and for women &ge;50 years were 67 and 90 percent.",
"   </p>",
"   <p>",
"    Since the prevalence of epithelial ovarian cancer is low, the utility of the symptom index in an average risk population has been questioned. A case control study compared 812 women with epithelial ovarian cancer with 1313 women from the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/20\">",
"     20",
"    </a>",
"    ]. Sensitivity for epithelial ovarian cancer in stage",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    was 62 percent and for stage",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    was 70 percent; the specificity was 95 percent for all stages. For different age groups, the sensitivity and specificity for ages 55 to 74 were 66 and 96 percent and for ages 35 to 54 were 69 and 94 percent. Using this average risk study population for comparison, the positive predictive value of the symptom index was 0.8 to 1.1 percent for all ovarian cancers and 0.2 to 0.5 for stage",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    disease. From a clinical perspective, the symptom index is best utilized when it is the first step in a sequential process that includes measurement of CA 125 and ultrasound imaging for women with a positive symptom index [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combined use of CA 125 and the symptoms index for epithelial ovarian cancer may have better diagnostic performance than either test alone. In a prospective study, 75 patients with pelvic masses who were subsequently diagnosed with epithelial ovarian cancer and 254 high risk controls were evaluated with the symptom index and a serum CA 125 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/22\">",
"     22",
"    </a>",
"    ]. The symptom index had lower sensitivity and specificity for epithelial ovarian cancer than an abnormal CA 125 (64 and 88 versus 79 and 95 percent), although 11 percent had a positive symptom index and negative CA 125 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/22\">",
"     22",
"    </a>",
"    ]. The combination of either a positive CA 125 or symptom index had a higher sensitivity, but a lower specificity than either test alone (89 and 84 percent). The combination of these tests needs to be evaluated in an average risk population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with symptoms suggestive of epithelial ovarian cancer should be evaluated with a physical examination, including an abdominal, pelvic, and rectovaginal examination as well as palpation of groin and supraclavicular lymph nodes. Findings suggestive of epithelial ovarian cancer include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Adnexal mass",
"     </li>",
"     <li>",
"      Abdominal ascites",
"     </li>",
"     <li>",
"      A mass in the mid to left upper abdomen, which may represent an omental cake",
"     </li>",
"     <li>",
"      Pleural effusion",
"     </li>",
"     <li>",
"      Groin or supraclavicular lymphadenopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the physical examination is normal, then, depending upon the clinical situation, we may wait two to four weeks to see if symptoms resolve or can be explained by another disorder. If they do not, we obtain an ultrasound examination of the pelvis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory and imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the findings on physical examination are abnormal or symptoms are persistent, then we evaluate patients with a transvaginal and transabdominal ultrasound examination to evaluate the ovaries and check for ascites (",
"    <a class=\"graphic graphic_table graphicRef79259 \" href=\"UTD.htm?1/0/1035\">",
"     table 4",
"    </a>",
"    ). Occasionally, abdominal or pelvic computed tomography (CT) is needed to help clarify ultrasound findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=see_link\">",
"     \"Sonographic differentiation of benign versus malignant adnexal masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We also suggest measuring the serum CA 125 concentration. This tumor marker used alone does not perform well for diagnosis or exclusion of epithelial ovarian cancer in premenopausal women. Moreover, half of patients with stage I epithelial ovarian cancer have a normal CA 125 level. Nevertheless, a very high level is suggestive of epithelial ovarian cancer and a baseline value is useful in monitoring women who are subsequently diagnosed with epithelial ovarian cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link&amp;anchor=H11#H11\">",
"     \"Screening for ovarian cancer\", section on 'CA 125'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8563758\">",
"    <span class=\"h2\">",
"     Recommendations from expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expert panels endorse the use of symptoms as a prompt for evaluation for epithelial ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. The Gynecologic Cancer Foundation, American Cancer Society, and Society of Gynecologic Oncologists issued a consensus statement regarding early symptoms in 2007 (",
"    <a class=\"graphic graphic_table graphicRef76135 \" href=\"UTD.htm?28/28/29132\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, since 2008, the National Comprehensive Cancer Network has included symptoms associated with epithelial ovarian cancer without other obvious source of malignancy as an indication for a work-up to exclude epithelial ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     REFERRAL TO A GYNECOLOGIC ONCOLOGIST",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Obstetricians and Gynecologists (ACOG) has published guidelines to help predict when ovarian or adnexal masses are likely to be malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23927/abstract/28\">",
"     28",
"    </a>",
"    ]. ACOG recommends that all women with masses suspicious for cancer undergo consultation or referral to a gynecologic oncologist. This recommendation is based on consistent evidence from studies showing that surgical treatment by nongynecologic oncologists, and by low volume providers, contributes to suboptimal surgical management and shorter median survival. The guidelines are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef55063 \" href=\"UTD.htm?7/38/7787\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link&amp;anchor=H5379833#H5379833\">",
"     \"Approach to the patient with an adnexal mass\", section on 'Referral to a specialist'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30905?source=see_link&amp;anchor=H15998736#H15998736\">",
"     \"Management of an adnexal mass\", section on 'Referral to a specialist'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/1/11283?source=see_link\">",
"       \"Patient information: Ovarian cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/15/6386?source=see_link\">",
"       \"Patient information: Ovarian cancer screening (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=see_link\">",
"       \"Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of early detection of epithelial ovarian cancer is to improve prognosis by diagnosing the disease while it is confined to the ovary or when the disease volume is low. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Role of early detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most women with epithelial ovarian cancer have abdominal symptoms prior to their diagnosis. These symptoms are often gastrointestinal or urinary, rather than gynecologic. (See",
"      <a class=\"local\" href=\"#H8563498\">",
"       'Presence of early symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bloating, increased abdominal size, urinary urgency or frequency, difficulty eating or feeling full, and abdominal or pelvic pain occur in many gastrointestinal disorders, but are also common in women with epithelial ovarian cancer. In particular, epithelial ovarian cancer should be suspected when these symptoms coexist with other symptoms, occur almost daily, and are more severe than expected. (See",
"      <a class=\"local\" href=\"#H8563498\">",
"       'Presence of early symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A symptom index has been developed to aid clinicians in evaluating women for early symptoms of epithelial ovarian cancer. Further validation studies are needed for this index and it is not yet recommended for routine clinical use. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Symptom index'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest physical examination, pelvic ultrasound examination, and measurement of serum CA 125 for further evaluation of women with persistent symptoms that are suggestive of epithelial ovarian cancer. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Laboratory and imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/1\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/2\">",
"      Goff BA, Muntz HG. Screening and early diagnosis of ovarian cancer. Women's Health in Primary Care 2005; 8:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/3\">",
"      Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer 2000; 89:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/4\">",
"      Olson SH, Mignone L, Nakraseive C, et al. Symptoms of ovarian cancer. Obstet Gynecol 2001; 98:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/5\">",
"      Vine MF, Ness RB, Calingaert B, et al. Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor. Gynecol Oncol 2001; 83:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/6\">",
"      Yawn BP, Barrette BA, Wollan PC. Ovarian cancer: the neglected diagnosis. Mayo Clin Proc 2004; 79:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/7\">",
"      Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004; 291:2705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/8\">",
"      Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007; 109:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/9\">",
"      Bankhead CR, Kehoe ST, Austoker J. Symptoms associated with diagnosis of ovarian cancer: a systematic review. BJOG 2005; 112:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/10\">",
"      Smith LH, Morris CR, Yasmeen S, et al. Ovarian cancer: can we make the clinical diagnosis earlier? Cancer 2005; 104:1398.",
"     </a>",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/statfacts/html/ovary.html (Accessed on May 26, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/12\">",
"      Hoskins WJ. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol 1994; 55:S91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/13\">",
"      Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/14\">",
"      Gilbert L, Basso O, Sampalis J, et al. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol 2012; 13:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/15\">",
"      Ramirez PT, Frumovitz M, Wolf JK, Levenback C. Laparoscopic port-site metastases in patients with gynecological malignancies. Int J Gynecol Cancer 2004; 14:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/16\">",
"      Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med 2009; 6:e1000114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/17\">",
"      Han LY, Karavasilis V, Hagen Tv, et al. Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy. Eur J Cancer 2010; 46:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/18\">",
"      Bankhead CR, Collins C, Stokes-Lampard H, et al. Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG 2008; 115:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/19\">",
"      Hippisley-Cox J, Coupland C. Identifying women with suspected ovarian cancer in primary care: derivation and validation of algorithm. BMJ 2012; 344:d8009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/20\">",
"      Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS. Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst 2010; 102:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/21\">",
"      Cass I, Karlan BY. Ovarian cancer symptoms speak out--but what are they really saying? J Natl Cancer Inst 2010; 102:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/22\">",
"      Andersen MR, Goff BA, Lowe KA, et al. Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer 2008; 113:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/23\">",
"      American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011; 117:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/24\">",
"      Redman C, Duffy S, Bromham N, et al. Recognition and initial management of ovarian cancer: summary of NICE guidance. BMJ 2011; 342:d2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/25\">",
"      Morgan RJ Jr, Alvarez RD, Armstrong DK, et al. Epithelial ovarian cancer. J Natl Compr Canc Netw 2011; 9:82.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.wcn.org/articles/types_of_cancer/ovarian/symptoms/index.html (Accessed on May 26, 2011).",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23927/abstract/28\">",
"      American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011; 117:742.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5472 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-BE0BA8F269-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_23_23927=[""].join("\n");
var outline_f23_23_23927=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8563428\">",
"      EVIDENCE REGARDING EARLY SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8563498\">",
"      Presence of early symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Role of early detection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL APPROACH TO SYMPTOM RECOGNITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Symptom index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory and imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8563758\">",
"      Recommendations from expert groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      REFERRAL TO A GYNECOLOGIC ONCOLOGIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5472\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5472|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/43/15038\" title=\"table 1\">",
"      Staging ovarian peritoneal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/5/27740\" title=\"table 2\">",
"      Ovarian cancer survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/6/6251\" title=\"table 3\">",
"      Ovarian cancer symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/0/1035\" title=\"table 4\">",
"      Sonographic findings ovarian CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/28/29132\" title=\"table 5\">",
"      Consensus statement ov ca",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/38/7787\" title=\"table 6\">",
"      Referral to gyn oncologist",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=related_link\">",
"      Approach to the patient with an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30905?source=related_link\">",
"      Management of an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/1/11283?source=related_link\">",
"      Patient information: Ovarian cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=related_link\">",
"      Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/15/6386?source=related_link\">",
"      Patient information: Ovarian cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=related_link\">",
"      Screening for ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=related_link\">",
"      Sonographic differentiation of benign versus malignant adnexal masses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_23_23928="Muscle phosphorylase deficiency (glycogen storage disease V, McArdle disease)";
var content_f23_23_23928=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Muscle phosphorylase deficiency (glycogen storage disease V, McArdle disease)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/23/23928/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/23/23928/contributors\">",
"     Basil T Darras, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/23/23928/contributors\">",
"     William J Craigen, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/23/23928/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/23/23928/contributors\">",
"     Sihoun Hahn, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/23/23928/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/23/23928/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/23/23928/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycogen is the stored form of glucose and serves as a buffer for glucose needs. It is composed of long polymers of a 1-4 linked glucose, interrupted by a 1-6 linked branch point every four to ten residues. Glycogen is formed in periods of dietary carbohydrate loading and broken down when glucose demand is high or dietary availability is low (",
"    <a class=\"graphic graphic_figure graphicRef81164 \" href=\"UTD.htm?4/62/5089\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are a number of inborn errors of glycogen metabolism that result from mutations in genes for virtually all of the proteins involved in glycogen synthesis, degradation, or regulation. Those disorders that result in abnormal storage of glycogen are known as glycogen storage diseases (GSDs). They have largely been categorized by number according to the chronology of recognition of the responsible enzyme defect (",
"    <a class=\"graphic graphic_table graphicRef54417 \" href=\"UTD.htm?37/36/38477\">",
"     table 1",
"    </a>",
"    ). The age of onset varies from in utero to adulthood.",
"   </p>",
"   <p>",
"    Glycogen is most abundant in liver and muscle, which are most affected by these disorders. The physiologic importance of a given enzyme in liver and muscle determines the clinical manifestations of the disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main role of glycogen in the liver is to store glucose for release to tissues that are unable to synthesize significant amounts during fasting. The major manifestations of disorders of glycogen metabolism affecting the liver are hypoglycemia and hepatomegaly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link\">",
"       \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glycogen is the primary source of energy for high intensity muscle activity by providing substrates for the generation of ATP. The major manifestations of disorders of glycogen metabolism affecting muscle are muscle cramps, exercise intolerance and easy fatigability, and progressive weakness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review muscle phosphorylase (myophosphorylase) deficiency (GSD V, MIM #232600), also known as McArdle disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/1\">",
"     1",
"    </a>",
"    ]. An overview of glycogen storage disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphorylase catalyzes the removal of 1,4-glucosyl residues from the outer branches of the glycogen molecule, thereby liberating glucose-1-phosphate. The degradation of glycogen continues until the peripheral branches of glycogen have been shortened to approximately four glucosyl units.",
"   </p>",
"   <p>",
"    Phosphorylase exists in three distinct isozymes encoded by three genes localized to different chromosomes. Human mature muscle has only a single phosphorylase isozyme, the gene for which has been mapped to chromosome 11q13 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/2\">",
"     2",
"    </a>",
"    ]. By comparison, three different isozymes have been identified on polyacrylamide slab gel electrophoresis in brain and cardiac muscle tissues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A fast-migrating \"brain\" isozyme comprises most of the phosphorylase activity in heart and brain.",
"     </li>",
"     <li>",
"      A slow-migrating isozyme (identical to muscle phosphorylase) comprises approximately 10 percent of the total enzymatic activity in heart and brain. Mutations in the muscle isozyme may therefore result in partial heart and brain involvement.",
"     </li>",
"     <li>",
"      An intermediate hybrid of the muscle and brain isozymes comprises approximately 30 percent of total heart and brain activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Heart involvement has been documented in a single fatal infantile variant [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inheritance is autosomal recessive, although rare cases of symptomatic heterozygotes are reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Apparent autosomal dominant inheritance (pseudodominance) has been noted in some families, a situation that may result if one parent is affected and the other is a heterozygote [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. The disorder is caused by mutations in the single gene encoding the muscle isoform of phosphorylase (muscle glycogen phosphorylase, PYGM), located at 11q13 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of mutations of myophosphorylase have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/9-15\">",
"     9-15",
"    </a>",
"    ]. The most common mutation in affected Caucasian individuals in Europe and the United States (US) converts an arginine residue to a stop codon (R50X) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/14,16\">",
"     14,16",
"    </a>",
"    ] at codon 50 in exon 5. The second most common mutant allele in these populations, accounting for about 9 percent of all mutations, is the p.Gly205Ser. Approximately 64 percent of Japanese patients often have a single codon deletion (p.Phe710del) within exon 17 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/11,17\">",
"     11,17",
"    </a>",
"    ]. Two patients with compound heterozygosity for one of the common mutations on one allele and novel splicing mutations in introns 3 and 5 on the other allele were both reported to have a milder phenotype with unusually high exercise capacity, probably related to the ameliorating effect of minimal myophosphorylase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However,",
"    <span class=\"nowrap\">",
"     genotype/phenotype",
"    </span>",
"    correlation has otherwise not been possible in McArdle disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/14,19,20\">",
"     14,19,20",
"    </a>",
"    ]. Nevertheless, the identification of these mutations has facilitated carrier detection and has proven diagnostically valuable.",
"   </p>",
"   <p>",
"    Disease severity has been correlated with the genotype at the angiotensin converting enzyme (ACE) locus, where an",
"    <span class=\"nowrap\">",
"     insertion/deletion",
"    </span>",
"    variant (the D allele) associated with modestly increased ACE activity is found more commonly in Spanish and Italian patients with more severe symptoms and reduced exercise tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myophosphorylase deficiency usually presents in adolescence or early adulthood with exercise intolerance, fatigue, myalgia, cramps, myoglobinuria, poor endurance, muscle swelling, and fixed weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/1\">",
"     1",
"    </a>",
"    ]. Some older patients may present with progressive weakness without history of cramps or myoglobinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/9,23\">",
"     9,23",
"    </a>",
"    ]. In addition, four children have been reported with respiratory insufficiency, generalized weakness and hypotonia noted at or shortly after birth, leading to death in infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/3,24\">",
"     3,24",
"    </a>",
"    ]. In another child (14 months old) transient elevation of creatine kinase (CK) was observed during febrile episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with McArdle disease, stiffness or weakness of exercising muscles can be induced by either brief periods of intense isometric exercise or by less intense but sustained dynamic exercise.",
"   </p>",
"   <p>",
"    A \"second wind\" phenomenon is experienced by patients with McArdle disease. This phenomenon is defined by the finding that brief rest after the development of muscle stiffness and myalgias can lead to the resumption of physical activity without significant symptoms. This \"second wind\" can be explained by increased blood flow, enhanced delivery of free fatty acids with concurrent activation of fatty acid metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/26\">",
"     26",
"    </a>",
"    ], and also increased glucose utilization.",
"   </p>",
"   <p>",
"    One study examined the clinical findings of 112 patients with McArdle disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fixed weakness affecting proximal more than distal muscles (which was more often noted in older patients) was noted in 28 percent of patients.",
"     </li>",
"     <li>",
"      In 85 percent, the disease onset was before the age of 15 years, and in 50 percent, the diagnosis was made between 10 and 30 years of age.",
"     </li>",
"     <li>",
"      Myoglobinuria was found in 50 percent, half of whom (27 percent of total) developed renal failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"       \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      53 percent had a positive family history.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another study of 80 McArdle disease patients, permanent weakness was noted in 11 percent of subjects after the age of 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The characteristics of pain were examined in 24 patients with McArdle disease; 23 reported pain [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/28\">",
"     28",
"    </a>",
"    ]. In 15 patients, the pain was intermittent and exercise-induced; however, in eight patients, permanent pain was a major clinical symptom, albeit not related to age or disease duration.",
"   </p>",
"   <p>",
"    At rest, the serum CK is usually elevated in most patients; by comparison, the resting CK is usually normal in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    palmitoyltransferase deficiency. Increased levels are observed even between episodes of myoglobinuria in patients with phosphorylase deficiency.",
"   </p>",
"   <p>",
"    The risk of complications during childbirth and delivery does not appear to be increased in women with McArdle disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carriers of McArdle disease are not likely to become symptomatic. In a study of oxidative capacity and lactate production during maximal cycle exercise in eight patients with McArdle disease, seven single phosphorylase gene mutation carriers and 11 healthy subjects, heterozygotes had maximal oxidative capacity and peak lactate responses identical to healthy subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/30\">",
"     30",
"    </a>",
"    ]. Although manifesting carriers of McArdle disease have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/31\">",
"     31",
"    </a>",
"    ], the studies were limited by the lack of molecular genetic investigations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myophosphorylase deficiency is suspected on the basis of the history of exercise-induced symptoms. A variety of diagnostic tests may be helpful.",
"   </p>",
"   <p>",
"    A minimally invasive approach to the diagnosis of suspected myophosphorylase deficiency involves initial forearm muscle exercise testing, which, if suggestive of myophosphorylase deficiency, is followed by genetic testing. The ethnic background of the patient should be taken into consideration when screening for mutations in genomic DNA isolated from blood or muscle. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Genetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A more invasive approach is to proceed to muscle biopsy with biochemical or histochemical analysis that includes testing for myophosphorylase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Forearm exercise test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The forearm ischemic lactate test is usually diagnostic of phosphorylase deficiency, showing a flat venous lactate curve. One study, for example, found no rise in venous lactate after ischemic forearm exercise in 93 percent of patients; the rise was reduced in the remainder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, most patients with McArdle disease experience muscle pain and cramps during the ischemic forearm exercise test. In addition, acute compartment syndrome has been reported after this test in a patient with McArdle disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/32\">",
"     32",
"    </a>",
"    ]. Therefore, we suggest that a non-ischemic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/33\">",
"     33",
"    </a>",
"    ], or minimally ischemic, forearm exercise test be performed in patients with a suspected diagnosis of McArdle disease. The test should be discontinued if the patient complains of muscle pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cramps during the exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common mutations in the gene for myophosphorylase may be detected by analysis of DNA obtained from peripheral blood leukocytes. As an example, in one study of 32 patients in the United States, 24 of whom had muscle biopsy documented myophosphorylase deficiency, a mutation in the myophosphorylase gene was detectable in 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/5\">",
"     5",
"    </a>",
"    ]. Improved testing methods, such as sequence analysis or high-resolution melting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/34\">",
"     34",
"    </a>",
"    ], have increased the detection frequency to 97 to 100 percent of cases. However, given the variable frequency of phosphorylase gene mutations in different populations, the ethnic background of the patient should be taken into consideration when screening for mutations in genomic DNA isolated from blood or muscle. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Genetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Muscle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle biopsy in phosphorylase deficiency may reveal focal subsarcolemmal and intermyofibrillar accumulations (\"blebs\") of normally structured glycogen. The amount of glycogen is either normal or moderately increased to approximately twice normal.",
"   </p>",
"   <p>",
"    Histochemical staining of muscle frozen sections for phosphorylase reveals no activity in muscle fibers in most cases, except in patients where there is some residual enzyme activity and also in muscle biopsies with a significant number of regenerating fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/9\">",
"     9",
"    </a>",
"    ]. Regenerating fibers may be positive histochemically because of the existence of a fetal isozyme immunologically different from mature muscle phosphorylase. Regenerating fibers usually are numerous in muscle biopsy specimens after an episode of myoglobinuria. Thus, a muscle biopsy performed shortly after an episode of rhabdomyolysis may provide a false-positive histochemical reaction for phosphorylase [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In classic cases, biochemical determination of phosphorylase activity reveals no detectable activity; in some, however, there may be up to 10 percent of normal residual enzyme activity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nonmuscle tissue analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphorylase activity is normal in erythrocytes, platelets, and cultured skin fibroblasts from McArdle patients; a finding probably related to the existence of non-muscle isozymes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Electromyography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The resting electromyogram (EMG) in patients with muscle phosphorylase deficiency is abnormal; it is characterized by myotonic discharges, fibrillations, and positive waves in approximately one half of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EMG usually is not needed if a metabolic myopathy is suspected at presentation. In such patients, EMG findings are nonspecific and forearm exercise test, genetic testing,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    muscle biopsy are far more informative. However, EMG may be obtained in patients with progressive or static muscle weakness who do not have cramps, pain, \"second wind\" phenomenon",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    myoglobinuria, and in whom metabolic myopathy may not be suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nuclear magnetic resonance spectroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;31P-nuclear magnetic resonance spectroscopy (MRS) has been reported to be abnormal in phosphorylase deficiency. Affected patients exhibit a lack of cellular acidification during ischemic exercise and a significant drop of the",
"    <span class=\"nowrap\">",
"     PCr/Pi",
"    </span>",
"    ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/38\">",
"     38",
"    </a>",
"    ]. 31P-nuclear MRS is a nonvalidated research test and not widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     POTENTIAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential therapies that have been tried in patients with muscle phosphorylase deficiency include manipulation of diet, moderate aerobic exercise, and supplementation with creatine and vitamin B6. While there is limited evidence to suggest that some of these therapies may be beneficial (sucrose supplementation before exercise, moderate exercise, creatine supplementation), the potential adverse effects (eg, weight gain, rhabdomyolysis) have yet to be fully elucidated.",
"   </p>",
"   <p>",
"    Based upon the observation that increasing copies of the D allele of the ACE locus is associated with disease severity, especially in women, preliminary results suggest benefits from treatment with the ACE inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest a trial of a diet consisting of 40 percent carbohydrate, 30 to 35 percent fat, and 25 to 30 percent protein to our patients with muscle phosphorylase deficiency. Low-carbohydrate diets should be avoided by patients with muscle phosphorylase deficiency. On the contrary, we suggest the ingestion of sucrose five minutes before all types of dynamic exercise. The dose of sucrose is 37 grams in adolescents and adults and about 18 to 20 grams in young children (the optimal dose in children has not been determined). Sucrose should be used in moderation to avoid excessive weight gain.",
"   </p>",
"   <p>",
"    The potential benefits of oral sucrose administration were demonstrated in a trial that assigned 12 patients with McArdle disease, in random order, to either sucrose (75 grams) or an artificially sweetened placebo solution in 660 mL of beverage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients served as their own controls and exercised by cycling at a constant work-load (50 watts). Exertion was significantly better tolerated after drinking the sucrose solution; peak heart rates were lower (by a mean of 35 beats per minute) and the patients' perceptions of the amount of exertion was also less than with placebo.",
"   </p>",
"   <p>",
"    A similar trial in six patients compared two sucrose regimens (75 grams 40 minutes before exercise and 37 grams five minutes before exercise) with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/41\">",
"     41",
"    </a>",
"    ]. Both sucrose regimens were associated with decreased peak heart rate, improved exercise tolerance, and lack of a \"second wind\" phenomenon, but perceived exertion and heart rate were consistently lower when sucrose was administered five minutes before exercise.",
"   </p>",
"   <p>",
"    Despite these promising short-term results, sucrose supplementation has limitations. It is not likely to prevent muscle damage from exercise that is static (eg, weight lifting) or unanticipated, has the potential to cause weight gain, and could interfere with mobilizing lipid stores during prolonged exercise.",
"   </p>",
"   <p>",
"    Oral administration of glucose or fructose has not resulted in consistent improvement and has caused significant weight gain. D-ribose or branched chain amino acids have not improved exercise capacity. High-fat, low-carbohydrate diets have also been ineffective.",
"   </p>",
"   <p>",
"    There is a case report of a single patient who improved with a high-protein diet [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/42\">",
"     42",
"    </a>",
"    ]. However, in an open, crossover trial in which seven patients with McArdle disease were randomly assigned to follow a carbohydrate- or protein-rich diet for three days before testing, the carbohydrate diet was associated with improved maximal work capacity and exercise tolerance, but the protein diet was not [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/43\">",
"     43",
"    </a>",
"    ]. The authors speculate that the carbohydrate diet also may help to prevent exercise-induced muscle injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with McArdle disease should moderate their physical activity and engage in low-level warm-up before any planned moderate exercise. Although the evidence is limited, routine moderate aerobic exercise may be beneficial in patients with McArdle disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. This was demonstrated in a series of eight patients with McArdle disease who exercised by pedaling a stationary cycle for 30 to 40 minutes per session four times a week at 60 to 70 percent of maximal heart rate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/44\">",
"     44",
"    </a>",
"    ]. After 14 weeks of training, average work capacity, oxygen uptake, and cardiac output increased by 36, 14 and 15 percent, respectively, compared with pretraining levels. Exercise was well tolerated, and no patients developed pain, cramping, or increased serum creatine kinase levels related to the prescribed exercise.",
"   </p>",
"   <p>",
"    While these results suggest that aerobic exercise should be a part of therapy for patients with McArdle disease, further confirmation of benefit in larger controlled trials is needed and the risk of rhabdomyolysis, if any, must be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Creatine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary supplementation with creatine may be beneficial. A double-blind, placebo-controlled, crossover study of the effects of low-dose (60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) oral creatine supplementation in nine patients with McArdle disease demonstrated an increase in ischemic, isometric forearm exercise capacity but no improvement in nonischemic isometric exercise or in cycle exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/47\">",
"     47",
"    </a>",
"    ]. The effects appear to be dose-limited since exercise tolerance worsened in response to the daily administration of high-dose creatine (150",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    in a follow-up study [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional studies are needed before creatine supplementation can be recommended for patients with McArdle disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vitamin B6",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because myophosphorylase complexes with vitamin B6 and accounts for a substantial proportion of body stores, supplementation of vitamin B6 has been postulated to possibly improve muscle function, resulting in less muscle fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/49\">",
"     49",
"    </a>",
"    ]. In a case report, withdrawal of B6 supplements led to increased episodes of muscle cramping, a subjective increase in weakness, and decreased muscle strength during ischemic forearm muscle testing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/50\">",
"     50",
"    </a>",
"    ]. Despite this finding, we feel that vitamin B6 supplementation is unlikely to be effective in this disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Aminoglycosides",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is known that aminoglycosides may induce full-length protein synthesis in genetic disorders by reading through stop codon mutations. In one study, treatment of four patients with stop mutations with daily intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    for 10 consecutive days failed to correct the myophosphorylase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27617010\">",
"    <span class=\"h1\">",
"     OTHER MANAGEMENT ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27617138\">",
"    <span class=\"h2\">",
"     General anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe perioperative problems are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/51\">",
"     51",
"    </a>",
"    ]. However, general anesthesia, particularly with muscle relaxants and inhaled anesthetics, has the potential to cause acute rhabdomyolysis that can result in myoglobinuria and even acute renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/52\">",
"     52",
"    </a>",
"    ]. There are also case reports of malignant hyperthermia in patients with McArdle disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/53\">",
"     53",
"    </a>",
"    ]. Prophylactic measures can be taken to prevent these potential complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=see_link\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link\">",
"     \"Susceptibility to malignant hyperthermia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33834?source=see_link\">",
"     \"Overview of complications occurring in the post-anesthesia care unit\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19178?source=see_link\">",
"     \"Postoperative fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/9/10394?source=see_link\">",
"     \"Perioperative care of the surgical patient with neurologic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27617145\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several case reports of statin-induced myopathy, including severe rhabdomyolysis, in patients with McArdle disease and carriers of mutations that cause metabolic myopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23928/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. Thus, this class of lipid-lowering drugs should be used with caution in these populations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link\">",
"     \"Drug-induced myopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Muscle phosphorylase (myophosphorylase) deficiency, also known as glycogen storage disease V and McArdle disease, is an autosomal recessive disease. It is caused by mutations in the gene encoding the muscle phosphorylase, located on chromosome 11. A variety of mutations have been described; the frequency of specific mutations varies depending upon the ethnic background of the patient. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myophosphorylase deficiency usually presents in adolescence or early adulthood with exercise intolerance, fatigue, myalgia, cramps, myoglobinuria, poor endurance, muscle swelling, and fixed weakness. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myophosphorylase deficiency is suspected on the basis of the history of exercise-induced symptoms. A variety of diagnostic tests may be helpful including forearm exercise testing, genetic testing, and muscle biopsy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a minimally invasive approach to the diagnosis, beginning with a non-ischemic or minimally ischemic forearm exercise test, followed by genetic testing as indicated (taking into consideration the ethnic background of the patient). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Forearm exercise test'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A more invasive approach involves muscle biopsy with histochemical and biochemical testing for myophosphorylase. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Muscle biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low carbohydrate diets should be avoided in patients with muscle phosphorylase deficiency. We suggest a trial of diet consisting of 40 percent carbohydrate, 30 to 35 percent fat, and 25 to 30 percent protein for patients with muscle phosphorylase deficiency (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diet'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the ingestion of sucrose five minutes before all types of dynamic exercise (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diet'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with McArdle disease should moderate their physical activity and engage in low-level warm-up before any planned moderate exercise. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The benefits of moderate aerobic exercise, creatine supplementation, treatment with ACE inhibitors, and vitamin B6 supplementation for patients with muscle phosphorylase deficiency remain unproven. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Exercise'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Creatine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Vitamin B6'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/1\">",
"      McArdle B. Myopathy due to a defect in muscle glycogen breakdown. Clin Sci 1951; 10:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/2\">",
"      Lebo RV, Gorin F, Fletterick RJ, et al. High-resolution chromosome sorting and DNA spot-blot analysis assign McArdle's syndrome to chromosome 11. Science 1984; 225:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/3\">",
"      DiMauro S, Hartlage PL. Fatal infantile form of muscle phosphorylase deficiency. Neurology 1978; 28:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/4\">",
"      Schmidt B, Servidei S, Gabbai AA, et al. McArdle's disease in two generations: autosomal recessive transmission with manifesting heterozygote. Neurology 1987; 37:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/5\">",
"      el-Schahawi M, Tsujino S, Shanske S, DiMauro S. Diagnosis of McArdle's disease by molecular genetic analysis of blood. Neurology 1996; 47:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/6\">",
"      Chui LA, Munsat TL. Dominant inheritance of McArdle syndrome. Arch Neurol 1976; 33:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/7\">",
"      Papadimitriou A, Manta P, Divari R, et al. McArdle's disease: two clinical expressions in the same pedigree. J Neurol 1990; 237:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/8\">",
"      Tsujino S, Shanske S, DiMauro S. Molecular genetic heterogeneity of myophosphorylase deficiency (McArdle's disease). N Engl J Med 1993; 329:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/9\">",
"      Bartram C, Edwards RH, Clague J, Beynon RJ. McArdle's disease: a nonsense mutation in exon 1 of the muscle glycogen phosphorylase gene explains some but not all cases. Hum Mol Genet 1993; 2:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/10\">",
"      Bruno C, Lanzillo R, Biedi C, et al. Two new mutations in the myophosphorylase gene in Italian patients with McArdle's disease. Neuromuscul Disord 2002; 12:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/11\">",
"      Tsujino S, Shanske S, Nonaka I, DiMauro S. The molecular genetic basis of myophosphorylase deficiency (McArdle's disease). Muscle Nerve 1995; 3:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/12\">",
"      G&aacute;mez J, Rubio JC, Mart&iacute;n MA, et al. Two novel mutations in the muscle glycogen phosphorylase gene in McArdle's disease. Muscle Nerve 2003; 28:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/13\">",
"      Mart&iacute;n MA, Rubio JC, Wevers RA, et al. Molecular analysis of myophosphorylase deficiency in Dutch patients with McArdle's disease. Ann Hum Genet 2004; 68:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/14\">",
"      Bruno C, Cassandrini D, Martinuzzi A, et al. McArdle disease: the mutation spectrum of PYGM in a large Italian cohort. Hum Mutat 2006; 27:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/15\">",
"      Rubio JC, Lucia A, Fern&aacute;ndez-Cadenas I, et al. Novel mutation in the PYGM gene resulting in McArdle disease. Arch Neurol 2006; 63:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/16\">",
"      Rubio JC, Garcia-Consuegra I, Nogales-Gadea G, et al. A proposed molecular diagnostic flowchart for myophosphorylase deficiency (McArdle disease) in blood samples from Spanish patients. Hum Mutat 2007; 28:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/17\">",
"      Sugie H, Sugie Y, Ito M, et al. Genetic analysis of Japanese patients with myophosphorylase deficiency (McArdle's disease): single-codon deletion in exon 17 is the predominant mutation. Clin Chim Acta 1995; 236:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/18\">",
"      Vissing J, Duno M, Schwartz M, Haller RG. Splice mutations preserve myophosphorylase activity that ameliorates the phenotype in McArdle disease. Brain 2009; 132:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/19\">",
"      Dimaur S, Andreu AL, Bruno C, Hadjigeorgiou GM. Myophosphorylase deficiency (glycogenosis type V; McArdle disease). Curr Mol Med 2002; 2:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/20\">",
"      Mart&iacute;n MA, Rubio JC, Buchbinder J, et al. Molecular heterogeneity of myophosphorylase deficiency (McArdle's disease): a genotype-phenotype correlation study. Ann Neurol 2001; 50:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/21\">",
"      Martinuzzi A, Sartori E, Fanin M, et al. Phenotype modulators in myophosphorylase deficiency. Ann Neurol 2003; 53:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/22\">",
"      Rubio JC, G&oacute;mez-Gallego F, Santiago C, et al. Genotype modulators of clinical severity in McArdle disease. Neurosci Lett 2007; 422:217.",
"     </a>",
"    </li>",
"    <li>",
"     DiMauro S, Bresolin N. Phosphorylase deficiency. In: Myology, Engel A, Banker B (Eds), McGraw-Hill, New York 1986. p.1585.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/24\">",
"      Milstein JM, Herron TM, Haas JE. Fatal infantile muscle phosphorylase deficiency. J Child Neurol 1989; 4:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/25\">",
"      Ito Y, Saito K, Shishikura K, et al. A 1-year-old infant with McArdle disease associated with hyper-creatine kinase-emia during febrile episodes. Brain Dev 2003; 25:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/26\">",
"      &Oslash;rngreen MC, Jeppesen TD, Andersen ST, et al. Fat metabolism during exercise in patients with McArdle disease. Neurology 2009; 72:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/27\">",
"      Nadaj-Pakleza AA, Vincitorio CM, Lafor&ecirc;t P, et al. Permanent muscle weakness in McArdle disease. Muscle Nerve 2009; 40:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/28\">",
"      Rommel O, Kley RA, Dekomien G, et al. Muscle pain in myophosphorylase deficiency (McArdle's disease): the role of gender, genotype, and pain-related coping. Pain 2006; 124:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/29\">",
"      Quinlivan R, Buckley J, James M, et al. McArdle disease: a clinical review. J Neurol Neurosurg Psychiatry 2010; 81:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/30\">",
"      Andersen ST, Dun&oslash; M, Schwartz M, Vissing J. Do carriers of PYGM mutations have symptoms of McArdle disease? Neurology 2006; 67:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/31\">",
"      Manfredi G, Silvestri G, Servidei S, et al. Manifesting heterozygotes in McArdle's disease: clinical, morphological and biochemical studies in a family. J Neurol Sci 1993; 115:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/32\">",
"      Lindner A, Reichert N, Eichhorn M, Zierz S. Acute compartment syndrome after forearm ischemic work test in a patient with McArdle's disease. Neurology 2001; 56:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/33\">",
"      Kazemi-Esfarjani P, Skomorowska E, Jensen TD, et al. A nonischemic forearm exercise test for McArdle disease. Ann Neurol 2002; 52:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/34\">",
"      Duno M, Quinlivan R, Vissing J, Schwartz M. High-resolution melting facilitates mutation screening of PYGM in patients with McArdle disease. Ann Hum Genet 2009; 73:292.",
"     </a>",
"    </li>",
"    <li>",
"     Bruno C, Hays AP, DiMauro S. Glycogen storage diseases of muscle. In: Neuromuscular disorders of infancy, childhood, and adolescence: A clinician's approach, Jones HR Jr, De Vivo DC, Darras BT (Eds), Butterworth Heinemann, Philadelphia 2003. p.813.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/36\">",
"      Servidei S, Shanske S, Zeviani M, et al. McArdle's disease: biochemical and molecular genetic studies. Ann Neurol 1988; 24:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/37\">",
"      McConchie SM, Coakley J, Edwards RH, Beynon RJ. Molecular heterogeneity in McArdle's disease. Biochim Biophys Acta 1990; 1096:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/38\">",
"      Argov Z, Bank WJ. Phosphorus magnetic resonance spectroscopy (31P MRS) in neuromuscular disorders. Ann Neurol 1991; 30:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/39\">",
"      Martinuzzi A, Liava A, Trevisi E, et al. Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease. Muscle Nerve 2008; 37:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/40\">",
"      Vissing J, Haller RG. The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. N Engl J Med 2003; 349:2503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/41\">",
"      Andersen ST, Haller RG, Vissing J. Effect of oral sucrose shortly before exercise on work capacity in McArdle disease. Arch Neurol 2008; 65:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/42\">",
"      Slonim AE, Goans PJ. Myopathy in McArdle's syndrome. Improvement with a high-protein diet. N Engl J Med 1985; 312:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/43\">",
"      Andersen ST, Vissing J. Carbohydrate- and protein-rich diets in McArdle disease: effects on exercise capacity. J Neurol Neurosurg Psychiatry 2008; 79:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/44\">",
"      Haller RG, Wyrick P, Taivassalo T, Vissing J. Aerobic conditioning: an effective therapy in McArdle's disease. Ann Neurol 2006; 59:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/45\">",
"      P&eacute;rez M, Foster C, Gonz&aacute;lez-Freire M, et al. One-year follow-up in a child with McArdle disease: exercise is medicine. Pediatr Neurol 2008; 38:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/46\">",
"      Quinlivan R, Vissing J, Hilton-Jones D, Buckley J. Physical training for McArdle disease. Cochrane Database Syst Rev 2011; :CD007931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/47\">",
"      Vorgerd M, Grehl T, Jager M, et al. Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial. Arch Neurol 2000; 57:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/48\">",
"      Vorgerd M, Zange J, Kley R, et al. Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study. Arch Neurol 2002; 59:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/49\">",
"      Beynon RJ, Bartram C, Hopkins P, et al. McArdle's disease: molecular genetics and metabolic consequences of the phenotype. Muscle Nerve 1995; 3:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/50\">",
"      Phoenix J, Hopkins P, Bartram C, et al. Effect of vitamin B6 supplementation in McArdle's disease: a strategic case study. Neuromuscul Disord 1998; 8:210.",
"     </a>",
"    </li>",
"    <li>",
"     GeneReviews topic on Glycogen Storage Disease Type V. file://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/books/NBK1344/.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/52\">",
"      Lobato EB, Janelle GM, Urdaneta F, Malias MA. Noncardiogenic pulmonary edema and rhabdomyolsis after protamine administration in a patient with unrecognized McArdle's disease. Anesthesiology 1999; 91:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/53\">",
"      Bollig G, Mohr S, Raeder J. McArdle's disease and anaesthesia: case reports. Review of potential problems and association with malignant hyperthermia. Acta Anaesthesiol Scand 2005; 49:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/54\">",
"      Livingstone C, Al Riyami S, Wilkins P, Ferns GA. McArdle's disease diagnosed following statin-induced myositis. Ann Clin Biochem 2004; 41:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/55\">",
"      Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006; 34:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/56\">",
"      Lorenzoni PJ, Silvado CE, Scola RH, et al. McArdle disease with rhabdomyolysis induced by rosuvastatin: case report. Arq Neuropsiquiatr 2007; 65:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23928/abstract/57\">",
"      Vladutiu GD. Genetic predisposition to statin myopathy. Curr Opin Rheumatol 2008; 20:648.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2909 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.97.94.19-CAE3B5A741-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_23_23928=[""].join("\n");
var outline_f23_23_23928=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Forearm exercise test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Muscle biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nonmuscle tissue analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Electromyography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nuclear magnetic resonance spectroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      POTENTIAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Creatine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vitamin B6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27617010\">",
"      OTHER MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27617138\">",
"      General anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27617145\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2909\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2909|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/62/5089\" title=\"figure 1\">",
"      Pathways of glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2909|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/36/38477\" title=\"table 1\">",
"      Disorders of glycogen - glucose metabolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=related_link\">",
"      Malignant hyperthermia: Clinical diagnosis and management of acute crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33834?source=related_link\">",
"      Overview of complications occurring in the post-anesthesia care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/9/10394?source=related_link\">",
"      Perioperative care of the surgical patient with neurologic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19178?source=related_link\">",
"      Postoperative fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=related_link\">",
"      Susceptibility to malignant hyperthermia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_23_23929="Treatment of cryptococcal meningoencephalitis in HIV-infected patients";
var content_f23_23_23929=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of cryptococcal meningoencephalitis in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/23/23929/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/23/23929/contributors\">",
"     Gary M Cox, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/23/23929/contributors\">",
"     John R Perfect, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/23/23929/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/23/23929/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/23/23929/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/23/23929/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/23/23929/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5056182\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptococcal meningoencephalitis is one of the leading opportunistic infections seen in patients with untreated AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/1\">",
"     1",
"    </a>",
"    ]. Management of these severely immunocompromised patients includes antifungal therapy combined with antiretroviral therapy (ART), with careful monitoring for complications related to the invasive fungal infection and the inflammatory syndromes secondary to immune recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic is devoted to the treatment of the HIV-infected host with cryptococcal meningitis. The epidemiology, clinical manifestations, diagnosis, treatment and management of complications of disease are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40919?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37254?source=see_link\">",
"     \"Microbiology and epidemiology of cryptococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38568?source=see_link\">",
"     \"Clinical management and monitoring during antifungal therapy of the HIV-infected patient with cryptococcal meningoencephalitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1025215\">",
"    <span class=\"h1\">",
"     ANTIFUNGAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary antifungal agents used for the treatment of cryptococcal meningoencephalitis include intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate or its lipid formulations, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    , and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    . Combination therapy with amphotericin B and flucytosine is fungicidal (inhibition leads to cell death), while fluconazole alone is only fungistatic (ie, inhibits without killing). Importantly, the use of a fungicidal regimen during the initial phase of therapy has been associated with better clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with baseline renal insufficiency, or those who are at risk for renal insufficiency, liposomal preparations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    are preferred.",
"   </p>",
"   <p>",
"    Echinocandin antifungals do not have any significant activity against Cryptococcus neoformans or C. gattii and should not be used to treat this infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1025257\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HIV-infected patient with advanced immunosuppression (CD4 cell count &lt;50",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    is at risk for severe cryptococcal meningoencephalitis, which is uniformly fatal within approximately two weeks if untreated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/5\">",
"     5",
"    </a>",
"    ]. Common presenting symptoms include fever, headache, photophobia, nausea, vomiting; patients with fulminant disease may present with coma. Predictors of poor outcome include high cerebrospinal fluid (CSF) cryptococcal antigen levels (titer &gt;1:1024), low body weight, and poor mental status on presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40919?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical trial data demonstrate that the optimal approach to treatment involves three phases: induction therapy for approximately two weeks followed by consolidative therapy for approximately eight weeks (",
"    <a class=\"graphic graphic_table graphicRef67612 \" href=\"UTD.htm?7/12/7373\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. Many HIV-infected patients with cryptococcal meningoencephalitis have a high burden of infection in the central nervous system (CNS) with yeast concentrations in the range of a million",
"    <span class=\"nowrap\">",
"     yeasts/mL",
"    </span>",
"    of CSF. This high burden of infection requires a combination treatment regimen with fungicidal activity such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    to rapidly sterilize the cerebrospinal fluid during induction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/3\">",
"     3",
"    </a>",
"    ]. Long-term maintenance (ie, suppressive) therapy is required to decrease the risk of relapse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43190?source=see_link\">",
"     \"Pharmacology of flucytosine (5-FC)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An important component of treatment of cryptococcal meningoencephalitis includes immune reconstitution with potent antiretroviral medications. However, the initiation of antiretroviral therapy (ART) can also lead to complications such as immune reconstitution inflammatory syndrome (IRIS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38568?source=see_link&amp;anchor=H14913615#H14913615\">",
"     \"Clinical management and monitoring during antifungal therapy of the HIV-infected patient with cryptococcal meningoencephalitis\", section on 'Immune reconstitution syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Effective patient management also requires careful evaluation for complications directly related to cryptococcal brain infections, such as increased intracranial pressure, which can lead to blindness, herniation, persistent headaches,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neuropathies, if untreated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38568?source=see_link&amp;anchor=H645246#H645246\">",
"     \"Clinical management and monitoring during antifungal therapy of the HIV-infected patient with cryptococcal meningoencephalitis\", section on 'Monitoring of intracranial pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1025336\">",
"    <span class=\"h1\">",
"     CLINICAL TRIAL DATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following section illustrates a few of the major trials that have guided the approach to therapeutic management of the HIV-infected patient with cryptococcal meningoencephalitis and form the foundation for the 2010 Infectious Diseases Society of America (IDSA) guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5331892\">",
"    <span class=\"h2\">",
"     Induction and consolidation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid sterilization of the cerebrospinal fluid (CSF) is linked to better survival rates and decreased rates of relapse among symptomatic patients with cryptococcal meningoencephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/3,8,9\">",
"     3,8,9",
"    </a>",
"    ]. Rapid sterilization also allows conversion from potentially toxic intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    to better tolerated oral agents. It is critically important to complete this two-week induction fungicidal regimen to optimize clinical outcomes. Thus, adverse events related to amphotericin B or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    should be actively managed, rather than switching to a less potent combination of drugs. (See",
"    <a class=\"local\" href=\"#H1386008\">",
"     'Adverse events'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Furthermore, additional weeks of induction therapy may be needed if: a) the patient remains comatose, b) the patient is clinically deteriorating, or c) if CSF culture results remain positive at the end of two weeks of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/2\">",
"     2",
"    </a>",
"    ]. Persistence of positive cultures may suggest the development of resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38568?source=see_link&amp;anchor=H14095130#H14095130\">",
"     \"Clinical management and monitoring during antifungal therapy of the HIV-infected patient with cryptococcal meningoencephalitis\", section on 'Drug resistance testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of fungicidal therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ) versus fungistatic therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ) for induction therapy was illustrated by a trial of 194 patients who were randomly assigned in a 2:1 ratio to either fluconazole (200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or amphotericin B (0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/10\">",
"     10",
"    </a>",
"    ]. Two important findings emerged from this trial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mortality was higher within the first two weeks among patients assigned to the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      arm compared with the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      arm (15 versus 8 percent).",
"     </li>",
"     <li>",
"      Compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      , treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      resulted in more rapid CSF sterilization (42 days versus 64 days).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A multicenter, double-blind trial evaluated the effectiveness of two weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (dosed higher at 0.7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day), with or without the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) as induction therapy in 381 HIV-infected patients with cryptococcal meningoencephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, the investigators compared eight weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (400 mg daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (400 mg daily) as consolidation therapy. This trial demonstrated that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CSF sterilization at two weeks occurred more frequently among patients receiving combination therapy compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      alone (60 versus 51 percent) without increased toxicity.",
"     </li>",
"     <li>",
"      Among the patients who underwent a repeat lumbar puncture at the end of the consolidation phase, the CSF culture was negative in 97 percent of patients on the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      arm (139 of 151) compared with 92 percent in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      group (93 of 101 patients). However, the data are somewhat limited since a significant percentage of patients assigned to the itraconazole and fluconazole arms did not undergo repeat lumbar puncture (35 and 26 percent, respectively). Clinical outcomes were similar between the two arms.",
"     </li>",
"     <li>",
"      Overall mortality was 5.5 percent within the first two weeks and 3.9 percent in the next eight weeks, with no significant difference between groups.",
"     </li>",
"     <li>",
"      A multivariate analysis demonstrated that the likelihood of CSF sterilization at the end of 10 weeks was highest among those patients who were assigned combination therapy followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to the trial described above [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/8\">",
"     8",
"    </a>",
"    ], a subsequent randomized open-label trial that compared the efficacy of three different induction therapy regimens showed a mortality benefit with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/11\">",
"     11",
"    </a>",
"    ]. In this trial, 299 HIV-positive patients with cryptococcal meningitis in Vietnam were randomly assigned to monotherapy with amphotericin B deoxycholate 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily for four weeks, combination therapy with amphotericin B deoxycholate 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily plus flucytosine 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three or four divided doses for two weeks, or amphotericin B deoxycholate 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    400 mg twice daily for two weeks. The following findings were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fewer deaths occurred by days 14 and 70 in patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      compared with patients who received amphotericin B monotherapy (15 versus 25 deaths by day 14, hazard ratio [HR] 0.57, 95% CI 0.30-1.08; 30 versus 44 deaths by day 70, HR 0.61, 95% CI 0.39-0.97). The mortality reduction was statistically significant at 70 days, but not at 14 days.",
"     </li>",
"     <li>",
"      Similar survival rates were observed in patients who received combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      and amphotericin B monotherapy.",
"     </li>",
"     <li>",
"      Combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      was associated with significantly increased rates of yeast clearance from the CSF (-0.42 log",
"      <sub>",
"       10",
"      </sub>",
"      colony forming units",
"      <span class=\"nowrap\">",
"       [CFU]/mL",
"      </span>",
"      per day compared with -0.31 log",
"      <sub>",
"       10",
"      </sub>",
"      <span class=\"nowrap\">",
"       CFU/mL",
"      </span>",
"      per day with amphotericin B monotherapy and -0.32 log",
"      <sub>",
"       10",
"      </sub>",
"      <span class=\"nowrap\">",
"       CFU/mL",
"      </span>",
"      per day with combination therapy with amphotericin B plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Rates of adverse events were similar in all groups, although neutropenia was more common in patients receiving combination therapy with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      (34 percent) or amphotericin B plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (32 percent) compared with amphotericin B monotherapy (19 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The superiority of combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    observed in this trial with respect to both mortality and rates of yeast clearance from the CSF strongly supports the recommendation to use this regimen for induction therapy of cryptococcal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4521551\">",
"     'Induction and consolidation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other trials have confirmed faster rates of CSF sterilization and lower rates of relapse with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    than amphotericin B alone [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/13-16\">",
"     13-16",
"    </a>",
"    ] and it is the combination of choice for the induction phase of therapy for cryptococcal meningitis. However since flucytosine is not available in some resource-limited settings, an important question is whether combination therapy with amphotericin B plus an azole results in comparable outcomes as amphotericin B plus flucytosine. This was addressed in a trial of 80 HIV-positive antiretroviral therapy (ART)-na&iuml;ve patients in South Africa who presented with cryptococcal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients were randomly assigned to four treatment arms for a two-week period of induction therapy: amphotericin B deoxycholate (0.7 to 1",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    plus flucytosine (25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally four times daily), amphotericin B deoxycholate (0.7 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (800 mg orally daily), amphotericin B deoxycholate (0.7 to 1",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    plus fluconazole (600 mg orally daily), or amphotericin B deoxycholate (0.7 to 1",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    (300 mg orally twice daily). There were no statistically significant differences in the rate of clearance of cryptococcal colony-forming units in CSF samples among the four treatment groups. Overall mortality was 12 percent at 2 weeks and 29 percent at 10 weeks, with no statistically significant differences among the groups.",
"   </p>",
"   <p>",
"    In an open-label study, 143 HIV-infected individuals in the United States or Thailand diagnosed with cryptococcal meningitis were randomly assigned to induction therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate (0.7",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    alone",
"    <strong>",
"     or",
"    </strong>",
"    amphotericin B deoxycholate (0.7",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    <strong>",
"     or",
"    </strong>",
"    amphotericin B deoxycholate (0.7",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    plus fluconazole (800",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/18\">",
"     18",
"    </a>",
"    ]. Following the induction phase of therapy, patients who initially received amphotericin B monotherapy were switched to fluconazole (400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for eight weeks, whereas those who initially received amphotericin B plus fluconazole were switched to consolidation therapy with fluconazole at the same dose to which they were randomly assigned (400 or 800 mg per day) for eight weeks. Although this study was not powered to demonstrate statistically significant differences in efficacy among the treatment arms, the arm that received high-dose fluconazole (800 mg per day) showed a trend towards better outcomes and the regimen was well tolerated.",
"   </p>",
"   <p>",
"    Another trial examined whether there may be a role for triple therapy with",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"      amphotericin B",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"      flucytosine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"      fluconazole",
"     </a>",
"    </span>",
"    compared with dual therapy, but no additional benefit was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal induction dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    is imprecise since 0.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    was not directly compared with 0.7",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    in the above mentioned clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/8\">",
"     8",
"    </a>",
"    ]. However, comparison of 0.7",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    with 1",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    amphotericin B demonstrated no difference in mortality at 10 weeks in a small trial among 64 HIV-infected patients with cryptococcal meningoencephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    is generally preferred over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    since the bioavailability of itraconazole varies significantly from person to person and drug monitoring is generally needed to assure appropriate serum levels have been achieved. In addition, itraconazole is associated with significant gastrointestinal symptoms, and its penetration into the CSF compartment is substantially less than fluconazole. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1026010\">",
"    <span class=\"h2\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early in the AIDS epidemic, primary therapy for cryptococcal meningoencephalitis was followed by frequent relapse after treatment discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/20\">",
"     20",
"    </a>",
"    ]. In 1991, 84 AIDS patients with a history of cryptococcal meningoencephalitis who were randomly assigned to 200 mg of daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (after primary induction and consolidative therapy), had a much lower incidence of relapse than those who were assigned to placebo (none versus 15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent trials comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    with either weekly intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    for cryptococcal meningoencephalitis demonstrated that fluconazole was the most efficacious antifungal agent for maintenance therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/7,13,21\">",
"     7,13,21",
"    </a>",
"    ]. For example, in one clinical trial of 108 HIV-infected patients, the relapse rate among those treated with itraconazole was 23 percent compared with 4 percent of those taking fluconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/13\">",
"     13",
"    </a>",
"    ]. The duration of maintenance therapy depends on the extent of immune recovery over time during ART. (See",
"    <a class=\"local\" href=\"#H7361633\">",
"     'Discontinuation of maintenance therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4519047\">",
"    <span class=\"h1\">",
"     APPROACH TO ANTIFUNGAL TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4521551\">",
"    <span class=\"h2\">",
"     Induction and consolidation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial preferred approach to the patient with cryptococcal meningoencephalitis includes combination antifungal therapy for the induction phase of therapy followed by consolidation therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      alone (",
"      <a class=\"graphic graphic_table graphicRef67612 \" href=\"UTD.htm?7/12/7373\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/2,7\">",
"       2,7",
"      </a>",
"      ]. Dosing for patients with renal insufficiency is discussed below. (See",
"      <a class=\"local\" href=\"#H5332994\">",
"       'Special treatment considerations'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For most patients, we recommend induction therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (0.7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily intravenously) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily in four divided doses orally) for a minimum of two weeks, followed by consolidation therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      at a dose of 400 mg orally once daily for a minimum of eight weeks.",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      is not available or if it is not tolerated, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (0.7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily intravenously) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (800 mg daily orally) for a minimum of two weeks, followed by consolidation therapy with fluconazole at a dose of 800 mg orally daily for a minimum of eight weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Induction therapy should be continued if clinical improvement is not yet observed or if cerebrospinal fluid (CSF) sterilization has not yet been achieved at two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/2\">",
"     2",
"    </a>",
"    ]. Use of intrathecal or intraventricular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    is not advised since systemic administration demonstrates good efficacy and these other direct routes can be associated with arachnoiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4522049\">",
"    <span class=\"h2\">",
"     Maintenance",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the completion of eight weeks, maintenance therapy with lower-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (200 mg daily) should be continued for long-term suppression (minimum of one year). Maintenance therapy can be discontinued if the patient has achieved sufficient immunologic recovery (ie, CD4 count &gt;100",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    with effective antiretroviral therapy (ART).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1386008\">",
"    <span class=\"h1\">",
"     ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    deoxycholate is frequently associated with electrolyte disturbances, anemia, renal insufficiency, and infusion site reactions, such as drug fever and rigors. The symptoms of an infusion reaction can be minimized or prevented by premedication with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (usual adult dose, 650 to 1000 mg orally)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (usual adult dose, 25 to 50 mg orally or intravenously). The risk of renal dysfunction associated with amphotericin B may be reduced with infusion of normal saline before and during therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link&amp;anchor=H10#H10\">",
"     \"Pharmacology of amphotericin B\", section on 'Infusion-related reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     Flucytosine",
"    </a>",
"    is mainly associated with gastrointestinal intolerance. Laboratory abnormalities include elevations in aminotransferases, anemia, leukopenia, and thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38568?source=see_link&amp;anchor=H14913503#H14913503\">",
"     \"Clinical management and monitoring during antifungal therapy of the HIV-infected patient with cryptococcal meningoencephalitis\", section on 'Monitoring for drug toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    is generally well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/18\">",
"     18",
"    </a>",
"    ]; patients occasionally may develop rash or abnormal aminotransferases.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    is associated with significant gastrointestinal intolerance and pedal edema and requires drug monitoring due to significant differences in bioavailability from person to person. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43190?source=see_link\">",
"     \"Pharmacology of flucytosine (5-FC)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patient and laboratory monitoring during",
"    <span class=\"nowrap\">",
"     induction/consolidation",
"    </span>",
"    and maintenance is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38568?source=see_link\">",
"     \"Clinical management and monitoring during antifungal therapy of the HIV-infected patient with cryptococcal meningoencephalitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5332994\">",
"    <span class=\"h1\">",
"     SPECIAL TREATMENT CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are special treatment considerations for the patient with established renal insufficiency or at risk of renal insufficiency and those patients who are intolerant of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5333070\">",
"    <span class=\"h2\">",
"     Patients at risk of renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the induction phase, lipid formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    are preferred for patients with baseline renal dysfunction and for those at risk for renal failure (eg, those with diabetes or uncontrolled hypertension, patients taking other nephrotoxic drugs, or patients with suspected HIV nephropathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. Compared with standard amphotericin B deoxycholate, lipid formulations of amphotericin B are associated with comparable efficacy and a lower incidence of acute kidney injury and renal tubular dysfunction, although at increased drug acquisition cost [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Infectious Diseases Society of America (IDSA) guidelines for HIV-infected patients with cryptococcal meningoencephalitis recommend 3 to 4",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/2\">",
"     2",
"    </a>",
"    ], while the Centers for Disease Control and Prevention (CDC) guidelines recommend a range of 4 to 6",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/7,24,26\">",
"     7,24,26",
"    </a>",
"    ]. We prefer liposomal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (3 to 4",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    IV) as a sufficient dose for induction based on clinical trials demonstrating clinical equivalence between this regimen and 0.7",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    of standard amphotericin B deoxycholate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     Amphotericin B lipid complex",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day intravenously) or Ambisome (6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily) are acceptable alternatives [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/2\">",
"     2",
"    </a>",
"    ]. One clinical trial that compared conventional amphotericin B with a liposomal formulation (ie, AmBisome), is highlighted below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The efficacy of conventional",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (0.7",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      was compared with two dosing regimens of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      (3",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      in the second arm; 6",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      in a third arm) among 267 HIV-infected patients with cryptococcal meningoencephalitis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/25\">",
"       25",
"      </a>",
"      ]. The mean serum creatinine amongst the trial participants was approximately 1.1",
"      <span class=\"nowrap\">",
"       mg/dL;",
"      </span>",
"      those with a serum creatinine greater than twice the normal range were excluded. Efficacy was similar in all arms, although there was less nephrotoxicity among patients in the 3",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      liposomal amphotericin B arm. Infusion reactions were less frequent in both liposomal treatment groups compared with the standard amphotericin B group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4652216\">",
"    <span class=\"h2\">",
"     Patients with established renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with renal dysfunction related to standard",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , the dose can be reduced by 50 percent or the standard dose can be given every other day. No dosage reductions are recommended for the various lipid formulations of amphotericin B. When economically feasible, lipid formulations of amphotericin B are preferred agents to use in patients at high risk for or with renal dysfunction.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     Flucytosine",
"    </a>",
"    does require dosage reduction in patients with renal insufficiency. Dosing recommendations for flucytosine are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a creatinine clearance of 20 to 40",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      37.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      is administered every 12 hours.",
"     </li>",
"     <li>",
"      For patients with a creatinine clearance of 10 to 20",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      37.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      is administered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Full dosing information is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43190?source=see_link&amp;anchor=H11#H11\">",
"     \"Pharmacology of flucytosine (5-FC)\", section on 'Dose modification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5332199\">",
"    <span class=\"h2\">",
"     Patients who are intolerant of amphotericin B and/or flucytosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other",
"    <span class=\"nowrap\">",
"     induction/consolidation",
"    </span>",
"    regimens for AIDS-associated cryptococcal meningoencephalitis have been studied for patients who are intolerant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    , with variable results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients intolerant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      : In an open-label study of high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (400 to 800 mg daily) combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      for",
"      <span class=\"nowrap\">",
"       induction/consolidative",
"      </span>",
"      therapy, 25 percent of patients still had positive cultures after 10 weeks of treatment and 13 percent died [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. In another small clinical trial, there were a lower number of deaths in the combination therapy arm compared with fluconazole alone (200 mg daily), but overall mortality rates were high (16 versus 40 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients intolerant of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      : When measuring rates of CSF sterilization, the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (400 mg daily) was found to be inferior to amphotericin B plus flucytosine for",
"      <span class=\"nowrap\">",
"       induction/consolidation,",
"      </span>",
"      but more effective than amphotericin B monotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/14\">",
"       14",
"      </a>",
"      ]. In terms of safety, the adverse events associated with amphotericin B plus fluconazole are mainly related to those expected with amphotericin B administration; fluconazole appears safe even at high doses of 400 to 800 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alternative regimens appear suboptimal for cerebrospinal fluid (CSF) sterilization compared with the recommended regimen discussed above. Thus, it is preferred to use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      , whenever feasible. Management of infusion reactions related to amphotericin B and cytopenias related to flucytosine are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link&amp;anchor=H10#H10\">",
"       \"Pharmacology of amphotericin B\", section on 'Infusion-related reactions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A full discussion of the alternative regimens is found within the IDSA guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7360694\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before starting antiretroviral therapy, drug-drug interactions must be checked and considered, particularly with the azoles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7362329\">",
"    <span class=\"h1\">",
"     THERAPEUTIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple complications can occur during antifungal therapy related to adverse drug-related events. In addition, patients with severe cryptococcal meningoencephalitis may develop increased intracranial pressure, which can lead to significant morbidity and mortality. Furthermore, some patients who initiate antiretroviral therapy (ART) can develop an inflammatory cerebrospinal fluid (CSF) profile with symptomatic increased intracranial pressure that is related to immune recovery. A full discussion of the symptoms, signs, and management of these complications and the timing of ART is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38568?source=see_link\">",
"     \"Clinical management and monitoring during antifungal therapy of the HIV-infected patient with cryptococcal meningoencephalitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361633\">",
"    <span class=\"h1\">",
"     DISCONTINUATION OF MAINTENANCE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small trials and observational studies suggest that maintenance therapy for cryptococcus can be safely discontinued in the majority of patients who have a CD4 cell count &gt;100",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    on effective antiretroviral therapy (ART) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. CD4 cell counts are usually monitored every three to four months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link&amp;anchor=H9#H9\">",
"     \"Patient monitoring during HIV antiretroviral therapy\", section on 'Frequency of laboratory monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective trial, 42 AIDS patients in Thailand were randomly assigned to continue or discontinue maintenance therapy when the CD4 cell count had risen to &gt;100",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      along with HIV viral suppression for three months [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/29\">",
"       29",
"      </a>",
"      ]. There were no relapses in either arm after 48 weeks of observation.",
"     </li>",
"     <li>",
"      In an observational study, 4 of 100 patients who discontinued maintenance therapy had a clinical relapse of cryptococcal infection [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an observational cohort of 358 patients who discontinued prophylaxis for various opportunistic infections, 39 had a history of cryptococcal meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/31\">",
"       31",
"      </a>",
"      ]. The absolute CD4 cell count was 100 to 199 in 8 patients and &gt;200 cells in 28 patients at the time of discontinuation of maintenance therapy; none of the patients relapsed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With discontinuation of azole maintenance therapy, the clinician must continue to follow patients closely, and reinitiation of maintenance therapy is indicated if the patient&rsquo;s CD4 cell count declines to less than 100",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    there is a significant rise in serum cryptococcal antigen titer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38568?source=see_link&amp;anchor=H14913545#H14913545\">",
"     \"Clinical management and monitoring during antifungal therapy of the HIV-infected patient with cryptococcal meningoencephalitis\", section on 'Monitoring of serum cryptococcal antigen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361640\">",
"    <span class=\"h1\">",
"     PRIMARY PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20033654\">",
"    <span class=\"h2\">",
"     Prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antifungal prophylaxis is not recommended by major guideline committees because of the lack of overall survival benefits associated with prophylaxis, the possibility of drug interactions, adverse effects, potential antifungal drug resistance, and cost [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/2,32\">",
"     2,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link&amp;anchor=H37#H37\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\", section on 'Cryptococcus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A Cochrane systematic review identified five randomized controlled trials using antifungal interventions for the primary prevention of cryptococcal disease in a total of 1316 HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/33\">",
"     33",
"    </a>",
"    ]. The incidence of cryptococcal disease decreased significantly in patients taking either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ; however, there was no significant effect on mortality. Similar findings regarding lack of survival benefit have been observed in resource-limited settings [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23929/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7361661\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cryptococcal meningoencephalitis occurs mainly in HIV-infected patients with advanced immunosuppression related to untreated AIDS. (See",
"      <a class=\"local\" href=\"#H5056182\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main antifungal agents used for the treatment of cryptococcal meningitis include intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (and its lipid formulations), oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      , and oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      . Amphotericin B and flucytosine are fungicidal (inhibition leads to cell death), while fluconazole is only fungistatic (ie, inhibits without killing). Lipid formulations of amphotericin B are preferred for patients with renal dysfunction and at risk for renal failure. (See",
"      <a class=\"local\" href=\"#H1025215\">",
"       'Antifungal agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cryptococcal meningoencephalitis is uniformly fatal if untreated. The therapeutic approach includes three phases: induction and consolidation for a total of 10 weeks to decrease early mortality and to rapidly sterilize the cerebrospinal fluid (CSF), followed by maintenance therapy to prevent relapse of infection. (See",
"      <a class=\"local\" href=\"#H1025257\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with cryptococcal meningoencephalitis, we recommend combination antifungal therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (0.7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily orally in four divided doses) during the two-week induction phase of therapy rather than amphotericin B deoxycholate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). If flucytosine is not available or if it is not tolerated, we recommend amphotericin B deoxycholate (0.7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV) plus fluconazole (800 mg daily orally) during the two-week induction phase of therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4521551\">",
"       'Induction and consolidation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If there is clinical improvement during the two-week induction therapy period,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      can be discontinued and oral azole therapy initiated for the eight-week consolidation phase of treatment. For patients who received amphotericin B plus flucytosine during the induction phase of therapy, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (400 mg per day orally) rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      during the consolidation phase (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients who received amphotericin B plus fluconazole during the induction phase of therapy, we suggest fluconazole at a dose of 800 mg orally daily rather than itraconazole or fluconazole at a lower dose (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4521551\">",
"       'Induction and consolidation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After the completion of",
"      <span class=\"nowrap\">",
"       induction/consolidation",
"      </span>",
"      phases of therapy, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (200 mg daily) for maintenance treatment compared with no therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Long-term chronic suppression should be continued for a minimum of one year. (See",
"      <a class=\"local\" href=\"#H1026010\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During the induction phase, lipid formulations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      are preferred for patients with baseline renal dysfunction and for those at risk for renal failure (eg, those with diabetes or uncontrolled hypertension or patients taking other nephrotoxic drugs). (See",
"      <a class=\"local\" href=\"#H5332994\">",
"       'Special treatment considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest discontinuation of maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      therapy in asymptomatic patients who have responded to antiretroviral therapy with a sustained increase in their CD4+ T lymphocytes for more than a year to &ge;100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Close follow-up is advised and fluconazole should be reinitiated if the CD4 cell count declines to &lt;100",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H7361633\">",
"       'Discontinuation of maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not recommend antifungal prophylaxis for primary prevention of cryptococcal disease (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7361640\">",
"       'Primary prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/1\">",
"      Bamba S, Lortholary O, Sawadogo A, et al. Decreasing incidence of cryptococcal meningitis in West Africa in the era of highly active antiretroviral therapy. AIDS 2012; 26:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/2\">",
"      Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010; 50:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/3\">",
"      Bicanic T, Harrison T, Niepieklo A, et al. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006; 43:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/4\">",
"      Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006; 43:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/5\">",
"      French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002; 16:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/6\">",
"      Anekthananon T, Manosuthi W, Chetchotisakd P, et al. Predictors of poor clinical outcome of cryptococcal meningitis in HIV-infected patients. Int J STD AIDS 2011; 22:665.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi_041009.pdf (Accessed on June 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/8\">",
"      van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/9\">",
"      Bicanic T, Muzoora C, Brouwer AE, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009; 49:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/10\">",
"      Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/11\">",
"      Day JN, Chau TT, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 2013; 368:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/12\">",
"      Perfect JR. Efficiently killing a sugar-coated yeast. N Engl J Med 2013; 368:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/13\">",
"      Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999; 28:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/14\">",
"      Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/15\">",
"      Milefchik E, Leal MA, Haubrich R, et al. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol 2008; 46:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/16\">",
"      Dromer F, Bernede-Bauduin C, Guillemot D, et al. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One 2008; 3:e2870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/17\">",
"      Loyse A, Wilson D, Meintjes G, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2012; 54:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/18\">",
"      Pappas PG, Chetchotisakd P, Larsen RA, et al. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2009; 48:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/19\">",
"      Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008; 47:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/20\">",
"      Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1991; 324:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/21\">",
"      Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med 1992; 326:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/22\">",
"      Diamond RD, Bennett JE. A subcutaneous reservoir for intrathecal therapy of fungal meningitis. N Engl J Med 1973; 288:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/23\">",
"      Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/24\">",
"      Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997; 11:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/25\">",
"      Hamill RJ, Sobel JD, El-Sadr W, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis 2010; 51:225.",
"     </a>",
"    </li>",
"    <li>",
"     Hamill R. Randomized, double-blind trial of liposomal amphotericin B and amphotericin B in acute cryptococcal meningitis in AIDS. Intersci Conf Antimicrob Agents Chemother 1999; 39:489 (Abstract # 1161).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/27\">",
"      Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994; 19:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/28\">",
"      Mayanja-Kizza H, Oishi K, Mitarai S, et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis 1998; 26:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/29\">",
"      Vibhagool A, Sungkanuparph S, Mootsikapun P, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis 2003; 36:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/30\">",
"      Mussini C, Pezzotti P, Mir&oacute; JM, et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis 2004; 38:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/31\">",
"      Kirk O, Reiss P, Uberti-Foppa C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002; 137:239.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.idsociety.org/Content.aspx?id=9088 (Accessed on December 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23929/abstract/33\">",
"      Chang LW, Phipps WT, Kennedy GE, Rutherford GW. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev 2005; :CD004773.",
"     </a>",
"    </li>",
"    <li>",
"     Parkes-Ratanshi R, Kamali A, Wakeham K, et al. Successful primary prevention of cryptococcal disease using fluconazole prophylaxis in HIV-infected patient Ugandan adults. Presented at the 16th Annual Conference on Retroviruses and Opportunistic Infections, Montreal, Canada February 8-11th, 2009; abstract #32.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83651 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-202.43.93.2-77D3A94D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_23_23929=[""].join("\n");
var outline_f23_23_23929=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7361661\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5056182\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1025215\">",
"      ANTIFUNGAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1025257\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1025336\">",
"      CLINICAL TRIAL DATA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5331892\">",
"      Induction and consolidation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1026010\">",
"      Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4519047\">",
"      APPROACH TO ANTIFUNGAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4521551\">",
"      Induction and consolidation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4522049\">",
"      Maintenance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1386008\">",
"      ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5332994\">",
"      SPECIAL TREATMENT CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5333070\">",
"      Patients at risk of renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4652216\">",
"      Patients with established renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5332199\">",
"      Patients who are intolerant of amphotericin B and/or flucytosine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7360694\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7362329\">",
"      THERAPEUTIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7361633\">",
"      DISCONTINUATION OF MAINTENANCE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7361640\">",
"      PRIMARY PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20033654\">",
"      Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7361661\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/83651\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/83651|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/12/7373\" title=\"table 1\">",
"      Rx crypto mening HIV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38568?source=related_link\">",
"      Clinical management and monitoring during antifungal therapy of the HIV-infected patient with cryptococcal meningoencephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40919?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37254?source=related_link\">",
"      Microbiology and epidemiology of cryptococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43190?source=related_link\">",
"      Pharmacology of flucytosine (5-FC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_23_23930="Injectable soft tissue fillers: Semipermanent agents";
var content_f23_23_23930=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Injectable soft tissue fillers: Semipermanent agents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/23/23930/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/23/23930/contributors\">",
"     Alastair Carruthers, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/23/23930/contributors\">",
"     Jean Carruthers, MD, FRCSC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/23/23930/contributors\">",
"     Shannon Humphrey, MD, FRCPC, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/23/23930/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/23/23930/contributors\">",
"     Jeffrey S Dover, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/23/23930/contributors\">",
"     Charles E Butler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/23/23930/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/23/23930/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/23/23930/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H44881949\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft-tissue fillers can be used alone or in combination with other aesthetic procedures to correct wrinkles and to restore tissue volume lost due to aging, lipoatrophy, or other causes. As opposed to permanent fillers, which persist indefinitely, semipermanent fillers are eventually resorbed by the body. Some agents, such as injectable collagen and hyaluronic acids, function primarily through a volume-filling effect. Others, including calcium hydroxylapatite and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/21/13651?source=see_link\">",
"     poly-L-lactic acid",
"    </a>",
"    fillers, act as scaffolds for endogenous collagen formation.",
"   </p>",
"   <p>",
"    The type of defect to be treated and the desired duration of effect influence the selection of a soft tissue filler (",
"    <a class=\"graphic graphic_table graphicRef71066 \" href=\"UTD.htm?22/45/23261\">",
"     table 1",
"    </a>",
"    ). Regardless of which agent is selected, clinician familiarity with the product utilized is crucial; improper injection techniques result in poor cosmetic outcomes and an increased incidence of adverse effects. Although some adverse effects resolve spontaneously with time, other adverse effects (eg, tissue necrosis) may result in permanent sequelae, such as scarring.",
"   </p>",
"   <p>",
"    The characteristics, efficacy, and adverse effects of several types of biodegradeable soft tissue fillers will be reviewed here. An overview of the principles of the clinical use and complications of soft tissue fillers, as well as a discussion of permanent soft tissue fillers are available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26024?source=see_link\">",
"     \"Injectable soft tissue fillers: Permanent agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27049?source=see_link\">",
"     \"Injectable soft tissue fillers: Overview of clinical use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44881956\">",
"    <span class=\"h1\">",
"     HYALURONIC ACID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyaluronic acid is a naturally occurring glycosaminoglycan that is an essential component of the extracellular matrix of the dermis. The molecule plays a key role in the maintenance of skin structure and function, and its high water-binding capacity is of value for the maintenance of moisture in the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The injection of exogenous hyaluronic acid into the skin effectively reduces visible signs of volume loss, while simultaneously providing a natural look and feel after treatment. These features, plus a relatively low risk for adverse effects have made hyaluronic acid-based fillers the most commonly used injectable soft tissue fillers worldwide (",
"    <a class=\"graphic graphic_table graphicRef71066 \" href=\"UTD.htm?22/45/23261\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/2\">",
"     2",
"    </a>",
"    ]. Although the US Food and Drug Administration has approved hyaluronic acid fillers only for the treatment of nasolabial folds, these products have been used for a variety of other indications, including marionette lines, glabellar rhytides, age-related volume loss in the dorsal hands, and augmentation of the lip, chin, and cheeks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/3\">",
"     3",
"    </a>",
"    ]. The clinical effects of treatment typically persist for 6 to 12 months (",
"    <a class=\"graphic graphic_table graphicRef71066 \" href=\"UTD.htm?22/45/23261\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44887349\">",
"    <span class=\"h2\">",
"     Product characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A shared feature of all hyaluronic acid fillers is the inclusion of hyaluronic acid that is chemically altered through cross-linking, which allows the molecule to resist rapid degradation by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=see_link\">",
"     hyaluronidase",
"    </a>",
"    and other factors in the skin. In contrast, naturally occurring or uncross-linked hyaluronic acid is degraded in skin within a few days.",
"   </p>",
"   <p>",
"    Examples of the chemical processes utilized for cross-linking hyaluronic acid include:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Butanediol diglycidyl ether (BDDE) cross-linking: Restylane",
"      <sup>",
"       &reg;",
"      </sup>",
"      , Perlane",
"      <sup>",
"       &reg;",
"      </sup>",
"      , and Juv&eacute;derm",
"      <sup>",
"       &reg;",
"      </sup>",
"     </li>",
"     <li>",
"      Divinyl sulfone cross-linking: Prevelle",
"      <sup>",
"       &reg;",
"      </sup>",
"      Silk, Captique",
"      <sup>",
"       &reg;",
"      </sup>",
"      , and Hylaform",
"      <sup>",
"       &reg;",
"      </sup>",
"     </li>",
"     <li>",
"      Biscarbodiimide cross-linking: Elevess",
"      <sup>",
"       &trade;",
"      </sup>",
"     </li>",
"     <li>",
"      1,2,7,8-diepoxyoctane cross-linking: Puragen",
"      <sup>",
"       &reg;",
"      </sup>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional factors distinguish the hyaluronic acid filling agents, including the source of hyaluronic acid and the expected duration of effect (",
"    <a class=\"graphic graphic_table graphicRef71066 \" href=\"UTD.htm?22/45/23261\">",
"     table 1",
"    </a>",
"    ). Moreover, specific gel characteristics, such as the concentration of hyaluronic acid and gel properties that affect product consistency, act in concert to determine the clinical behavior of each filling agent (",
"    <a class=\"graphic graphic_table graphicRef80284 \" href=\"UTD.htm?40/36/41548\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Origin &ndash;",
"      </strong>",
"      The chemical composition of hyaluronic acid is similar across species. Hylaform",
"      <sup>",
"       &reg;",
"      </sup>",
"      , an older form of hyaluronic acid filler, contains hyaluronic acid derived from rooster combs. The majority of hyaluronic acid-based filling agents now contain non-animal stabilized hyaluronic acid (NASHA) derived from the fermentation of Streptococcus equi bacteria.",
"     </li>",
"     <li>",
"      <strong>",
"       Concentration &ndash;",
"      </strong>",
"      The total concentration of hyaluronic acid in filling agents is readily available in package inserts. Provided other gel characteristics are similar, agents with higher concentrations of hyaluronic acid can be incompletely hydrated, resulting in a higher capacity for water-binding once placed in tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/5\">",
"       5",
"      </a>",
"      ]. This can manifest as slight swelling of the product after placement in the skin [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Consistency and flow &ndash;",
"      </strong>",
"      Factors such as particle size, gel hardness, and concentration of cross-linked hyaluronic acid affect the consistency and fluidity of hyaluronic acid fillers (",
"      <a class=\"graphic graphic_table graphicRef80284 \" href=\"UTD.htm?40/36/41548\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/1,5,6\">",
"       1,5,6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Particle size &ndash;",
"      </strong>",
"      Large particles provide greater filling power and more resistance to degradation in tissues, which may be beneficial for the treatment of deep skin folds and rhytides and for volumizing skin [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/1\">",
"       1",
"      </a>",
"      ]. Products that contain large particles require larger gauge needles (eg, 27-gauge needles) for injection, as opposed to the 30-gauge needles that can be used with smaller particle agents. Perlane",
"      <sup>",
"       &reg;",
"      </sup>",
"      is an example of a large particle gel.",
"      <br/>",
"      <br/>",
"      Small particle or nonparticulate gels are characterized by a smoother consistency. Juv&eacute;derm",
"      <sup>",
"       &reg;",
"      </sup>",
"      Ultra and Juv&eacute;derm",
"      <sup>",
"       &reg;",
"      </sup>",
"      Ultra Plus, which are nonparticulate gels, incorporate a relatively high degree of cross-linking to counterbalance the loss of filling power and product longevity that can result from the elimination of particles [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Gel hardness &ndash;",
"      </strong>",
"      Hard gels exhibit greater resistance to deformation, require greater pressure to inject to the skin, and tend to provide a firmer feel under the skin. Soft gels may be beneficial for the treatment of areas with thin skin, such as the periorbital area or lips [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/1\">",
"       1",
"      </a>",
"      ]. Restylane",
"      <sup>",
"       &reg;",
"      </sup>",
"      and Perlane",
"      <sup>",
"       &reg;",
"      </sup>",
"      are relatively hard gels.",
"     </li>",
"     <li>",
"      <strong>",
"       Degree of cross-linking &ndash;",
"      </strong>",
"      The amount of uncross-linked (soluble) and cross-linked (insoluble) hyaluronic acid in a gel influences gel viscosity [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/5\">",
"       5",
"      </a>",
"      ]. Decreasing the proportion of cross-linked hyaluronic acid contributes to a less viscous product and a smoother flow during injection, but may contribute to a shorter duration of effect [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/5,7\">",
"       5,7",
"      </a>",
"      ]. Decreasing the amount of cross-linked hyaluronic acid also decreases the hardness of a gel.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44881970\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of hyaluronic acid fillers has been primarily attributed to a space-filling effect of hyaluronic acid and water bound to hyaluronic acid molecules. However, a study that compared the histopathologic findings in forearm skin injected with a hyaluronic acid filler (Restylane",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) to sites injected isotonic saline found that the stimulation of collagen synthesis may contribute to treatment efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/8\">",
"     8",
"    </a>",
"    ]. The authors proposed that mechanical tension on fibroblasts, which has been associated with the regulation of collagen synthesis in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/9-11\">",
"     9-11",
"    </a>",
"    ], may contribute to the clinical effect of Restylane",
"    <sup>",
"     &reg;",
"    </sup>",
"    . Additional studies are necessary to determine whether similar findings occur with other hyaluronic acid filling agents and in facial skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44881984\">",
"    <span class=\"h2\">",
"     Formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of hyaluronic acid fillers are available (",
"    <a class=\"graphic graphic_table graphicRef71066 \" href=\"UTD.htm?22/45/23261\">",
"     table 1",
"    </a>",
"    ). The Juv&eacute;derm",
"    <sup>",
"     &reg;",
"    </sup>",
"    (Juv&eacute;derm",
"    <sup>",
"     &reg;",
"    </sup>",
"    Ultra, Juv&eacute;derm",
"    <sup>",
"     &reg;",
"    </sup>",
"    Ultra Plus, Juv&eacute;derm",
"    <sup>",
"     &reg;",
"    </sup>",
"    Ultra XC, and Juv&eacute;derm",
"    <sup>",
"     &reg;",
"    </sup>",
"    Ultra Plus XC) and Restylane",
"    <sup>",
"     &reg;",
"    </sup>",
"    (Restylane",
"    <sup>",
"     &reg;",
"    </sup>",
"    , Restylane-L",
"    <sup>",
"     &reg;",
"    </sup>",
"    , Perlane",
"    <sup>",
"     &reg;",
"    </sup>",
"    , and Perlane-L",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) lines are among the most commonly used products in the United States. Juvederm",
"    <sup>",
"     &reg;",
"    </sup>",
"    Ultra and Juvederm",
"    <sup>",
"     &reg;",
"    </sup>",
"    UltraPlus are also known as Juvederm",
"    <sup>",
"     &reg;",
"    </sup>",
"    24 HV and Juvederm",
"    <sup>",
"     &reg;",
"    </sup>",
"    30 HV, respectively.",
"   </p>",
"   <p>",
"    Examples of other hyaluronic acid agents used in soft tissue filling worldwide include Belotero",
"    <sup>",
"     &reg;",
"    </sup>",
"    Balance (Merz Pharmaceuticals, Greensboro, NC), Elevess&trade; (Anika Therapeutics, Bedford, MA), Puragen&trade; and Puragen&trade; Plus (Mentor Corporation, Santa Barbara, CA) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], Prevelle",
"    <sup>",
"     &reg;",
"    </sup>",
"    Silk (Mentor Corporation, Santa Barbara, CA), Revanesse",
"    <sup>",
"     &reg;",
"    </sup>",
"    (Prollenium Medical Technologies, Ontario), and Teosyal",
"    <sup>",
"     &reg;",
"    </sup>",
"    (Clarion Medical Technologies, Ontario). With the rise of the non-animal stabilized hyaluronic acid filling agents, use of Hylaform",
"    <sup>",
"     &reg;",
"    </sup>",
"    , an avian-derived filling agent, has declined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44881991\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of hyaluronic acid filling agents for soft tissue augmentation of the nasolabial folds and other sites has been documented in multiple randomized trials, uncontrolled studies, and case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/4,7,14-32\">",
"     4,7,14-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44887654\">",
"    <span class=\"h3\">",
"     Versus bovine collagen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials comparing the efficacy of hyaluronic acid fillers to bovine collagen, a filling agent that preceded the development of hyaluronic acid filling agents, for nasolabial folds have found superior results with hyaluronic acid fillers. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized, split-face trial of 439 patients with moderate to severe nasolabial folds, patients were treated with either one of three hyaluronic acid fillers (Juv&eacute;derm",
"      <sup>",
"       &reg;",
"      </sup>",
"      30, Juv&eacute;derm",
"      <sup>",
"       &reg;",
"      </sup>",
"      Ultra, or Juv&eacute;derm",
"      <sup>",
"       &reg;",
"      </sup>",
"      Ultra Plus) or bovine collagen (Zyplast",
"      <sup>",
"       &reg;",
"      </sup>",
"      ). Clinically significant improvement persisted for longer after treatment with the hyaluronic acid agents [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/22\">",
"       22",
"      </a>",
"      ]. Twenty-four weeks after the last treatment, 81 to 90 percent of nasolabial folds treated with the hyaluronic acid fillers maintained statistically significant improvement, compared to only 36 to 45 percent of nasolabial folds treated with bovine collagen. Treatment was well-tolerated in all groups. Juv&eacute;derm",
"      <sup>",
"       &reg;",
"      </sup>",
"      30 is not available in the United States.",
"     </li>",
"     <li>",
"      A randomized, split-face trial of 138 patients with mild to severe nasolabial folds treated with a hyaluronic acid filler (Restylane",
"      <sup>",
"       &reg;",
"      </sup>",
"      ) or bovine collagen (Zyplast",
"      <sup>",
"       &reg;",
"      </sup>",
"      ) found that the degree of improvement at two, four, and six months after treatment was superior for the hyaluronic acid filler [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/19\">",
"       19",
"      </a>",
"      ]. Six months after treatment, 67 percent of patients treated with bovine collagen had returned to baseline severity, compared with 30 percent of patients treated with hyaluronic acid. Patient tolerance to the treatments was similar; local adverse events were mild to moderate and resolved within seven days in most patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44887647\">",
"    <span class=\"h3\">",
"     Versus calcium hydroxylapatite",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of two randomized trials suggest that injectable calcium hydroxylapatite (Radiesse",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) may have a greater duration of effect than hyaluronic acid-based fillers in the treatment of nasolabial folds. (See",
"    <a class=\"local\" href=\"#H44882068\">",
"     'Calcium hydroxylapatite (Radiesse&reg;)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of 205 patients with moderate to severe nasolabial folds treated with calcium hydroxylapatite or hyaluronic acid (Perlane",
"      <sup>",
"       &reg;",
"      </sup>",
"      , Juv&eacute;derm",
"      <sup>",
"       &reg;",
"      </sup>",
"      24, or Juv&eacute;derm",
"      <sup>",
"       &reg;",
"      </sup>",
"      24HV), significantly greater proportions of patients treated with calcium hydroxylapatite than with hyaluronic acid were improved at all time points up to eight months [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/33\">",
"       33",
"      </a>",
"      ]. However, the changes in wrinkle severity scores were similar among all of the products. Juv&eacute;derm",
"      <sup>",
"       &reg;",
"      </sup>",
"      24 is not available in the United States, and Juv&eacute;derm",
"      <sup>",
"       &reg;",
"      </sup>",
"      24HV is equivalent to Juv&eacute;derm",
"      <sup>",
"       &reg;",
"      </sup>",
"      Ultra.",
"     </li>",
"     <li>",
"      The results of a split-face randomized trial of 60 patients with moderate to severe nasolabial folds treated calcium hydroxylapatite or hyaluronic acid (Restylane",
"      <sup>",
"       &reg;",
"      </sup>",
"      ) found that more nasolabial folds treated with calcium hydroxylapatite remained improved 12 months after the initial injection (79 versus 43 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/34\">",
"       34",
"      </a>",
"      ]. In addition, at the same time point, nasolabial folds treated with calcium hydroxylapatite treated exhibited superior results significantly more often than the sides treated with hyaluronic acid (47 versus 5 percent of patients).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1866561\">",
"    <span class=\"h3\">",
"     With lidocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Products that contain",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    have expanded the armamentarium of hyaluronic acid fillers and have made the injection of these fillers far less uncomfortable. The results of several randomized trials indicate that lidocaine-containing hyaluronic acid fillers reduce patient discomfort and can be used safely without affecting product efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/35-41\">",
"     35-41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1117199\">",
"    <span class=\"h3\">",
"     With botulinum toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with hyaluronic acid fillers and botulinum toxin may improve the longevity of treatment results when treating sites of dynamic wrinkles, such as glabellar lines [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/16,42\">",
"     16,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22778?source=see_link&amp;anchor=H4081889#H4081889\">",
"     \"Overview of botulinum toxin for cosmetic indications\", section on 'Soft-tissue augmentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44887668\">",
"    <span class=\"h2\">",
"     Use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some randomized trials have compared the efficacy of individual hyaluronic acid fillers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/13,20,21,43-45\">",
"     13,20,21,43-45",
"    </a>",
"    ], factors such as the type of defect to be corrected, treatment site, and preferred duration of effect are the most important factors to consider during treatment selection. Clinician familiarity with a product is also critical; improper injection technique can lead to poor results or adverse effects.",
"   </p>",
"   <p>",
"    The ideal placement and depth of injection is dependent on the defect and site treated. In vivo and ex vivo pathologic studies suggest that the subcutis and deep dermis are the primary sites of deposition of hyaluronic acid after injection into nasolabial folds [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. In contrast to treatment with Zyderm",
"    <sup>",
"     &reg;",
"    </sup>",
"    and CosmoDerm",
"    <sup>",
"     &reg;",
"    </sup>",
"    , overcorrection of defects is not required.",
"   </p>",
"   <p>",
"    Juv&eacute;derm",
"    <sup>",
"     &reg;",
"    </sup>",
"    , Restylane",
"    <sup>",
"     &reg;",
"    </sup>",
"    , and Perlane",
"    <sup>",
"     &reg;",
"    </sup>",
"    products are supplied in prefilled syringes. The manufacturers of these agents recommend the following dose guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Juv&eacute;derm",
"      <sup>",
"       &reg;",
"      </sup>",
"      Ultra, Juv&eacute;derm",
"      <sup>",
"       &reg;",
"      </sup>",
"      Ultra Plus, Juv&eacute;derm",
"      <sup>",
"       &reg;",
"      </sup>",
"      Ultra XC, and Juv&eacute;derm",
"      <sup>",
"       &reg;",
"      </sup>",
"      Ultra Plus XC:",
"      <strong>",
"       no more than",
"      </strong>",
"      20 mL per 60 kg of patient weight should be administered per treatment session",
"     </li>",
"     <li>",
"      Restylane",
"      <sup>",
"       &reg;",
"      </sup>",
"      , Restylane-L",
"      <sup>",
"       &reg;",
"      </sup>",
"      , Perlane",
"      <sup>",
"       &reg;",
"      </sup>",
"      , and Perlane-L",
"      <sup>",
"       &reg;",
"      </sup>",
"      :",
"      <strong>",
"       no more than",
"      </strong>",
"      6 mL should be administered per treatment session",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hylaform",
"    <sup>",
"     &reg;",
"    </sup>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be given to patients with allergies to avian proteins (eg, eggs or feathers). Juv&eacute;derm",
"    <sup>",
"     &reg;",
"    </sup>",
"    , Restylane",
"    <sup>",
"     &reg;",
"    </sup>",
"    , and Perlane",
"    <sup>",
"     &reg;",
"    </sup>",
"    products are contraindicated in patients with a history of anaphylaxis, multiple severe allergies, and allergies to gram positive bacterial proteins. Additionally, Restylane",
"    <sup>",
"     &reg;",
"    </sup>",
"    and Perlane",
"    <sup>",
"     &reg;",
"    </sup>",
"    are contraindicated in patients with bleeding disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44881998\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent adverse effects associated with hyaluronic acid filling agents are transient and mild, and include pain bruising, edema, and erythema at the injection site [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Fan-like needle use, rapid injection (&gt;0.3",
"    <span class=\"nowrap\">",
"     mL/minute),",
"    </span>",
"    and high volume injections have been associated with increased rates of adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, noninflammatory nodules or a bluish discoloration of the skin (secondary to the Tyndall effect) can occur when injections are placed too superficially [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/49-52\">",
"     49-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delayed hypersensitivity and granulomatous reactions to hyaluronic acid filling agents are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/49,53-72\">",
"     49,53-72",
"    </a>",
"    ]. These reactions typically manifest as inflammatory papules or nodules that appear weeks to months after injection. Complications such as bacterial and mycobacterial infections or vascular occlusion resulting in tissue necrosis or compromise of the retinal artery are also uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/73-78\">",
"     73-78",
"    </a>",
"    ]. The development of lower eyelid xanthelasmata following periorbital injection of a hyaluronic acid filler has been reported in two patients; however, causality has not been confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1117242\">",
"    <span class=\"h2\">",
"     Reversal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Misplacement or excessive injection of hyaluronic acid fillers can be treated with injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=see_link\">",
"     hyaluronidase",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/50,51,80-85\">",
"     50,51,80-85",
"    </a>",
"    ]. Hyaluronidase appears to be well tolerated; local injection site reactions occur infrequently, and urticaria, angioedema, or anaphylaxis rarely occur [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/86\">",
"     86",
"    </a>",
"    ]. Due to the potential for anaphylaxis, patients should be prick tested to evaluate for immediate hypersensitivity reactions prior to the injection of hyaluronidase [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/87\">",
"     87",
"    </a>",
"    ]. The use of hyaluronidase to reverse the effects of hyaluronic acid fillers is not approved by the US Food and Drug Administration.",
"   </p>",
"   <p>",
"    The optimum dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=see_link\">",
"     hyaluronidase",
"    </a>",
"    has not been established; doses reported in the literature vary from less than 5 units to 75 units per injection site. Doses of 10 units were effective for the dissolution of a hyaluronic acid-based filler (Restylane",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) injected into forearm skin in a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/85\">",
"     85",
"    </a>",
"    ]; doses as low as 1.5 to 3 units may also be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=see_link\">",
"     Hyaluronidase",
"    </a>",
"    has also been used successfully in the management of a patient with a hyaluronic acid filler-induced granulomatous reaction that failed to improve with intralesional and topical corticosteroids, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and systemic antibiotic therapy, and a patient with a presumed hyaluronic acid embolic event in the distribution of the angular artery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/75,80\">",
"     75,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44882012\">",
"    <span class=\"h1\">",
"     COLLAGEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the advent of hyaluronic acid fillers, the use of collagen fillers has become less common. Collagen filling agents are associated a relatively shorter duration of effect, and skin testing is required prior to the use of bovine-derived agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33951301\">",
"    <span class=\"h2\">",
"     Formulations and use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Collagen derived from a variety of sources has been used for the correction of contour deficiencies of soft tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44882019\">",
"    <span class=\"h3\">",
"     Bovine collagen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bovine collagen was the first form of injectable collagen utilized for soft tissue augmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/89\">",
"     89",
"    </a>",
"    ]. The availability of bovine collagen fillers is limited; the products are no longer commercially available in the United States.",
"   </p>",
"   <p>",
"    Zyderm",
"    <sup>",
"     &reg;",
"    </sup>",
"    I (35",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    of bovine collagen plus 0.3%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    suspended in saline) is typically injected into the papillary dermis for the treatment of superficial rhytides, while Zyderm",
"    <sup>",
"     &reg;",
"    </sup>",
"    II (65",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    bovine collagen plus 0.3% lidocaine suspended in saline) is injected into the upper reticular dermis for deeper rhytides (",
"    <a class=\"graphic graphic_figure graphicRef54021 \" href=\"UTD.htm?23/19/23858\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/90\">",
"     90",
"    </a>",
"    ]. A third product, Zyplast",
"    <sup>",
"     &reg;",
"    </sup>",
"    , contains lidocaine and 35",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    bovine collagen cross-linked with glutaraldehyde, which results in a more viscous product with reduced susceptibility to degradation. Zyplast",
"    <sup>",
"     &reg;",
"    </sup>",
"    is injected into the mid to deep reticular dermis, and is typically used for deep lines and rhytides and lip augmentation.",
"   </p>",
"   <p>",
"    Zyderm",
"    <sup>",
"     &reg;",
"    </sup>",
"    I and Zyderm",
"    <sup>",
"     &reg;",
"    </sup>",
"    II contain a significant amount of saline, which is resorbed after injection. Thus, overcorrection of defects by approximately 100 percent for Zyderm",
"    <sup>",
"     &reg;",
"    </sup>",
"    I and 50 percent for Zyderm",
"    <sup>",
"     &reg;",
"    </sup>",
"    II is often performed. Overcorrection is not required for Zyplast",
"    <sup>",
"     &reg;",
"    </sup>",
"    .",
"   </p>",
"   <p>",
"    A disadvantage of bovine collagen fillers is the requirement for skin testing prior to treatment. Approximately 3 percent of the population will develop delayed hypersensitivity reactions following injection of bovine collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/49\">",
"     49",
"    </a>",
"    ]. Two skin tests separated by two to four weeks should be performed prior to injection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skin tests are performed by injecting 0.1 mL of bovine collagen into an inconspicuous site, such as the ventral forearm. A positive test is characterized by the development of erythema and edema at the site of injection; reactions usually occur after two to three days. Treatment can begin two weeks after the second negative test. Patients who have not been treated for one year should be given one repeat skin test [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/90\">",
"     90",
"    </a>",
"    ]. The package inserts for Zyderm",
"    <sup>",
"     &reg;",
"    </sup>",
"    and Zyplast",
"    <sup>",
"     &reg;",
"    </sup>",
"    recommend administering no more than 30 mL of Zyderm",
"    <sup>",
"     &reg;",
"    </sup>",
"    I, 15 mL of Zyderm",
"    <sup>",
"     &reg;",
"    </sup>",
"    II, or 30 mL of any combination of the three bovine collagen agents within one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44882026\">",
"    <span class=\"h3\">",
"     Human collagen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human-derived collagen was developed to reduce the risk of antigenicity associated with bovine collagen fillers. Skin testing is not required for these agents.",
"   </p>",
"   <p>",
"    Initially, human collagen fillers were derived from human cadavers. Concern for the transmission of infection led to the development of CosmoDerm",
"    <sup>",
"     &reg;",
"    </sup>",
"    I, CosmoDerm",
"    <sup>",
"     &reg;",
"    </sup>",
"    II, and CosmoPlast",
"    <sup>",
"     &reg;",
"    </sup>",
"    , which are derived from a single line of human neonatal foreskin fibroblasts. Similar to the bovine collagen fillers, these products are no longer commercially available in the United States.",
"   </p>",
"   <p>",
"    CosmoDerm",
"    <sup>",
"     &reg;",
"    </sup>",
"    I and CosmoDerm",
"    <sup>",
"     &reg;",
"    </sup>",
"    II contain 0.3%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    and 35",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    or 65",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    of collagen, respectively. CosmoDerm",
"    <sup>",
"     &reg;",
"    </sup>",
"    I is primarily used in the papillary dermis for fine lines and superficial rhytides, while CosmoDerm",
"    <sup>",
"     &reg;",
"    </sup>",
"    II is appropriate for injection into the mid-dermis for slightly deeper defects (",
"    <a class=\"graphic graphic_figure graphicRef54021 \" href=\"UTD.htm?23/19/23858\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/91\">",
"     91",
"    </a>",
"    ]. CosmoPlast",
"    <sup>",
"     &reg;",
"    </sup>",
"    contains collagen cross-linked by glutaraldehyde and is most appropriate for injection into the deep dermis and the treatment of deep lines, such as nasolabial folds. Analogous to the bovine collagen products, overcorrection of defects is typically performed during treatment with CosmoDerm",
"    <sup>",
"     &reg;",
"    </sup>",
"    I and CosmoDerm",
"    <sup>",
"     &reg;",
"    </sup>",
"    II, and is not necessary for treatment with CosmoPlast",
"    <sup>",
"     &reg;",
"    </sup>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44882033\">",
"    <span class=\"h3\">",
"     Autologous collagen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of autologous collagen products has become rare due to the complexity of producing these agents and the wide availability of hyaluronic acid fillers. Isolagen",
"    <sup>",
"     &reg;",
"    </sup>",
"    , a previously marketed autologous collagen product, is no longer available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44882040\">",
"    <span class=\"h3\">",
"     Porcine collagen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evolence",
"    <sup>",
"     &reg;",
"    </sup>",
"    (ColBar LifeScience Ltd., Herzliyha, Israel) is a porcine collagen filler that exhibited equivalent efficacy to Restylane",
"    <sup>",
"     &reg;",
"    </sup>",
"    in a split-face randomized trial of 149 patients with moderate nasolabial folds [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/92\">",
"     92",
"    </a>",
"    ]. Evolence",
"    <sup>",
"     &reg;",
"    </sup>",
"    is not available for purchase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44882047\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although collagen products can be used safely and effectively for soft tissue augmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/93\">",
"     93",
"    </a>",
"    ], they appear to be less effective than hyaluronic acid fillers. A systematic review of randomized trials found that the majority of randomized trials that compared collagen to hyaluronic acid fillers for the treatment of nasolabial folds concluded that hyaluronic acid fillers were associated with superior results [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H44887654\">",
"     'Versus bovine collagen'",
"    </a>",
"    above.) However, some clinicians have observed less bruising and edema after treatment with collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/49,91\">",
"     49,91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another type of filler, calcium hydroxylapatite (Radiesse",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) was more effective than human collagen (CosmoPlast",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) in a split-face randomized trial of 117 patients with moderate to deep nasolabial folds. Three months after treatment, the side of the face treated with calcium hydroxylapatite exhibited greater improvement than the side treated with CosmoPlast",
"    <sup>",
"     &reg;",
"    </sup>",
"    in 85 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/94\">",
"     94",
"    </a>",
"    ]. Bruising and edema occurred more frequently in the calcium hydroxylapatite group. (See",
"    <a class=\"local\" href=\"#H44882068\">",
"     'Calcium hydroxylapatite (Radiesse&reg;)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44882054\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects of collagen injections are immediate mild bruising, edema, and erythema. Symptoms typically resolve within a few days [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/95-99\">",
"     95-99",
"    </a>",
"    ]. In contrast, hypersensitivity reactions to bovine collagen typically present with prominent erythema and edema involving the treatment site within two weeks after treatment. Symptoms of hypersensitivity reactions usually improve over a few weeks, as the local inflammatory reaction destroys the implanted collagen. Intralesional corticosteroids, topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and systemic glucocorticoids have been used to accelerate improvement in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rare adverse effects of collagen injection include localized tissue necrosis and abscess formation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/100\">",
"     100",
"    </a>",
"    ]. In particular, necrosis has been linked to Zyplast",
"    <sup>",
"     &reg;",
"    </sup>",
"    injection into the glabella [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44882061\">",
"    <span class=\"h2\">",
"     Reversal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports of the successful use of collagenase clostridium histolyticum for the treatment of Dupuytren's contracture have led some authors to question whether this enzyme could be useful for reversing the effect of collagen fillers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/101-103\">",
"     101-103",
"    </a>",
"    ]. The efficacy and safety collagenase for this indication is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44882068\">",
"    <span class=\"h1\">",
"     CALCIUM HYDROXYLAPATITE (RADIESSE&reg;)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcium hydroxylapatite filler (Radiesse",
"    <sup>",
"     &reg;",
"    </sup>",
"    ; Bioform Medical, Inc., San Mateo, CA; formerly known as Radiance) is composed of synthetic, uniform, and smooth calcium hydroxylapatite microspheres suspended in an aqueous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/34/29218?source=see_link\">",
"     carboxymethylcellulose",
"    </a>",
"    gel carrier [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/104\">",
"     104",
"    </a>",
"    ]. US Food and Drug Administration approved uses of Radiesse",
"    <sup>",
"     &reg;",
"    </sup>",
"    include the correction of moderate to severe facial folds and wrinkles such as nasolabial folds, and the correction of facial lipoatrophy in patients with human immunodeficiency virus (HIV) infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33951425\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once injected into the skin, the carrier gel is gradually resorbed and the remaining calcium hydroxylapatite microspheres stimulate the local production of endogenous collagen. Eventually, the microspheres are degraded into calcium and phosphate ions and are excreted [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/105-107\">",
"     105-107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44882082\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of calcium hydroxylapatite for the treatment of nasolabial folds and other facial sites in healthy patients is supported by multiple studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/3,94,107-114\">",
"     3,94,107-114",
"    </a>",
"    ]. As an example, the benefit of this agent was evident in a cohort study of 1000 patients treated for a variety of cosmetic indications (most commonly nasolabial folds, marionette lines, and oral commissures) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/107\">",
"     107",
"    </a>",
"    ]. More than 80 percent of patients in the study reported persistence of treatment benefit after 12 months.",
"   </p>",
"   <p>",
"    Randomized trials comparing calcium hydroxylapatite to other temporary filling agents have also supported the efficacy of this product for nasolabial folds; calcium hydroxylapatite has exhibited greater duration of effect when compared to hyaluronic acid and human collagen fillers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/33,34,94\">",
"     33,34,94",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H44887647\">",
"     'Versus calcium hydroxylapatite'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H44882047\">",
"     'Efficacy'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    Several uncontrolled studies have documented beneficial effects of calcium hydroxylapatite injections for HIV-associated lipoatrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/108,115-119\">",
"     108,115-119",
"    </a>",
"    ]. In one open-label study of 100 patients with this disorder, treatment led to improvement in all patients through 12 months, and 91 percent of patients remained improved after 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33951353\">",
"    <span class=\"h2\">",
"     Use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiesse",
"    <sup>",
"     &reg;",
"    </sup>",
"    is supplied as a gel in a prefilled syringe; use of a 25 to 27 gauge needle is recommended for injection. A formulation of Radiesse",
"    <sup>",
"     &reg;",
"    </sup>",
"    that contains",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    is not available; however, premixing Radiesse",
"    <sup>",
"     &reg;",
"    </sup>",
"    with lidocaine prior to injection can be used to reduce patient discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/120\">",
"     120",
"    </a>",
"    ]. The depth of injection is subdermal (",
"    <a class=\"graphic graphic_figure graphicRef54021 \" href=\"UTD.htm?23/19/23858\">",
"     figure 1",
"    </a>",
"    ) and overcorrection of defects should be avoided. Massage of the treatment site immediately after injection facilitates even distribution of the product.",
"   </p>",
"   <p>",
"    Treatment with Radiesse",
"    <sup>",
"     &reg;",
"    </sup>",
"    is contraindicated in patients with a history of anaphylaxis, multiple severe allergies, or known hypersensitivity to any of the product components.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44882089\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injectable calcium hydroxylapatite is generally well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/121\">",
"     121",
"    </a>",
"    ]. Injection-site reactions, including transient erythema, edema, ecchymosis, pain on injection, and pruritus are the most frequently reported side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/104\">",
"     104",
"    </a>",
"    ]. Noninflammatory nodules secondary to aggregation of the filling agent can occur after treatment of the lips; the formation of nodules in other sites is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/107,108,111,113,114\">",
"     107,108,111,113,114",
"    </a>",
"    ]. One retrospective study that included 349 lip augmentation patients found an incidence of nodule formation of 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/107\">",
"     107",
"    </a>",
"    ]. The development of inflammatory nodules in the lip due to a foreign body reaction to calcium hydroxylapatite has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nodules can resolve over time; there is no injectable product that can be used to dissolve the product after injection. If treatment is desired, massage, needle disruption, or surgical excision can be utilized to accelerate resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. In one patient, a calcium hydroxylapatite nodule disappeared following treatment with a fractional carbon dioxide laser for skin laxity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although calcium hydroxylapatite implants are usually visible on computed tomography (CT) scans and are sometimes detectable on x-ray imaging, they do not appear to be detrimental for the interpretation of these studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/124,125\">",
"     124,125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2827103\">",
"    <span class=\"h2\">",
"     Large particle calcium hydroxylapatite",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvement in nasolabial folds and mid-facial atrophy after injection with a large particle formulation of calcium hydroxylapatite (Coaptite",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) has been reported in a few patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/126\">",
"     126",
"    </a>",
"    ]. US Food and Drug Administration approval for Coaptite",
"    <sup>",
"     &reg;",
"    </sup>",
"    is limited to the treatment of urinary incontinence, and additional studies are necessary to explore the efficacy and safety of this agent as a cosmetic filler. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44409?source=see_link\">",
"     \"Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44882103\">",
"    <span class=\"h1\">",
"     POLY-L-LACTIC ACID (SCULPTRA&reg;)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sculptra",
"    <sup>",
"     &reg;",
"    </sup>",
"    and Sculptra",
"    <sup>",
"     &reg;",
"    </sup>",
"    Aesthetic (Dermik",
"    <span class=\"nowrap\">",
"     Laboratories/Sanofi-Aventis,",
"    </span>",
"    Bridgewater, NJ) contain microparticles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/21/13651?source=see_link\">",
"     poly-L-lactic acid",
"    </a>",
"    (PLLA), a biocompatible and biodegradable synthetic polymer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/127\">",
"     127",
"    </a>",
"    ]. Sculptra",
"    <sup>",
"     &reg;",
"    </sup>",
"    is US Food and Drug Administration approved for the treatment of HIV-associated lipoatrophy; Sculptra",
"    <sup>",
"     &reg;",
"    </sup>",
"    Aesthetic is approved for the correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44882110\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technically, PLLA does not &ldquo;fill&rdquo; the skin. Once injected, PLLA induces a subclinical inflammatory response that stimulates fibroblast proliferation and collagen formation, leading to a progressive increase in volume of the dermis. PLLA is gradually degraded over the course of 9 to 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H799852\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of PLLA for HIV-associated facial lipoatrophy is supported by randomized trials and uncontrolled studies that have demonstrated improvement in patient appearance and cutaneous thickness [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/128-141\">",
"     128-141",
"    </a>",
"    ]. As an example, in an uncontrolled study of 61 HIV-positive patients who were treated with PLLA every three to six weeks over a five-month period, all patients improved after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of PLLA for nasolabial folds was established in a randomized trial of 233 patients who were given up to four treatment sessions with either PLLA or human collagen. Patients treated with PLLA exhibited statistically significant improvement in nasolabial fold severity over baseline at all study time points, and improvement was superior to collagen 3, 6, 9, and 13 months after treatment. Multiple other studies have supported the efficacy of PLLA for nasolabial folds, acne scars, facial asymmetry, and other cosmetic indications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/138,142-152\">",
"     138,142-152",
"    </a>",
"    ]. Clinical improvement has been documented for up to two years after PLLA treatment in immunocompetent and HIV-positive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/132,138,151\">",
"     132,138,151",
"    </a>",
"    ]. The duration of effect exceeds that of hyaluronic acid and collagen fillers (",
"    <a class=\"graphic graphic_table graphicRef71066 \" href=\"UTD.htm?22/45/23261\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800758\">",
"    <span class=\"h2\">",
"     Use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sculptra",
"    <sup>",
"     &reg;",
"    </sup>",
"    and Sculptra",
"    <sup>",
"     &reg;",
"    </sup>",
"    Aesthetic must be reconstituted with sterile water at least two hours prior to injection to ensure complete hydration of the product. The injection should be placed in the deep dermis or subcutaneous fat with a 26-gauge or larger needle (",
"    <a class=\"graphic graphic_figure graphicRef54021 \" href=\"UTD.htm?23/19/23858\">",
"     figure 1",
"    </a>",
"    ). When treating the nasolabial folds, injection is usually performed in a cross-hatch (grid-like) pattern.",
"   </p>",
"   <p>",
"    Because treatment results progressively improve over time, undercorrection of the defect is the goal. Of note, transient tissue edema may develop immediately after injection, resulting in the appearance of full correction. Subsequent treatments should be spaced by at least three weeks to allow for assessment of response.",
"   </p>",
"   <p>",
"    Treatment should also be avoided in patients with a history of keloidal or hypertrophic scarring and patients with a known hypersensitivity to any of the product components [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/153,154\">",
"     153,154",
"    </a>",
"    ]. In addition, we typically avoid the use of this agent in the lip and periorbital region due to an increased likelihood for nodule formation in these areas (see",
"    <a class=\"local\" href=\"#H800623\">",
"     'Adverse effects'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/150,152\">",
"     150,152",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800623\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential adverse effects of injection include hematoma, bruising, edema, discomfort, inflammation, and erythema [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/127\">",
"     127",
"    </a>",
"    ]. Another common complication is the occurrence of asymptomatic, subcutaneous papules weeks to months after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/127,155\">",
"     127,155",
"    </a>",
"    ]. In one series of 130 immunocompetent patients treated with PLLA, nodule formation occurred in 8.5 percent. Subcutaneous papule formation has been reported in 6 to 44 percent of patients treated for HIV-associated lipoatrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/156\">",
"     156",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proper dilution of the product, avoidance of poor injection technique (eg, superficial injections, overcorrection), and manual tissue massage immediately after injection may decrease the risk for this adverse effect nodule formation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/157\">",
"     157",
"    </a>",
"    ]. Nodules typically resolve spontaneously without intervention. Nodules that fail to resolve may require subcision (disruption of papules with a needle), excision, or intralesional corticosteroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/138,153,154\">",
"     138,153,154",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delayed appearance of granulomatous reactions has also been reported in a few patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/152,158-160\">",
"     152,158-160",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801577\">",
"    <span class=\"h1\">",
"     PLATELET-RICH FIBRIN MATRIX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet-rich fibrin matrices (PRFM), which can be created through the centrifugation of blood, may have utility for cosmetic soft tissue augmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/161\">",
"     161",
"    </a>",
"    ]. In a series of 15 patients, nasolabial wrinkle severity was significantly reduced after injection of autologous PRFM [",
"    <a class=\"abstract\" href=\"UTD.htm?23/23/23930/abstract/162\">",
"     162",
"    </a>",
"    ]. The authors proposed that growth factors released from the injected platelets may have contributed to treatment benefit. Additional studies are necessary to determine the safety and efficacy of PRFM for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33951432\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A variety of injectable filling agents are available for the treatment of prominent skin lines, fat atrophy, and other contour defects involving soft tissue. Semipermanent fillers are composed of biodegradable ingredients, such as hyaluronic acid, collagen, calcium hydroxylapatite, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/21/13651?source=see_link\">",
"       poly-L-lactic acid",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H44881949\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyaluronic acid-based fillers are the most common injectable agents used for soft tissue augmentation. A wide variety of products are commercially available. All hyaluronic acid fillers contain chemically cross-linked hyaluronic acid, which allows the product to resist immediate degradation. Factors such as the defect type and location, the preferred duration of effect, and clinician expertise with specific agents determine the most appropriate choice of agent. (See",
"      <a class=\"local\" href=\"#H44881956\">",
"       'Hyaluronic acid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transient bruising, discomfort, edema, and erythema are the most common adverse effects associated with the injection of hyaluronic acid fillers. Infrequently, patients may develop hypersensitivity reactions, granulomatous reactions, infections, or complications of vascular occlusion. (See",
"      <a class=\"local\" href=\"#H44887668\">",
"       'Use'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H44881998\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The effects of hyaluronic acid fillers diminish over time.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=see_link\">",
"       Hyaluronidase",
"      </a>",
"      injections are an option for the immediate removal of injected hyaluronic acid filling agents after improper placement. (See",
"      <a class=\"local\" href=\"#H1117242\">",
"       'Reversal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of collagen-based fillers declined after the development of hyaluronic acid fillers. These agents are less effective than hyaluronic acid fillers, and skin testing for hypersensitivity required prior to administration of bovine collagen is inconvenient for some patients. (See",
"      <a class=\"local\" href=\"#H44882012\">",
"       'Collagen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Calcium hydroxylapatite is effective for the correction of soft-tissue defects, including nasolabial folds and HIV-associated lipodystrophy. Calcium hydroxylapatite is injected subdermally, and overcorrection of defects should be avoided. Adverse nodule formation after treatment is most likely to occur after injection of the lips. (See",
"      <a class=\"local\" href=\"#H44882068\">",
"       'Calcium hydroxylapatite (Radiesse&reg;)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/21/13651?source=see_link\">",
"       poly-L-lactic acid",
"      </a>",
"      are long lasting; improvement has been documented in patients treated for HIV-associated lipoatrophy and other soft tissue defects two years after treatment. Injections should be placed into the deep dermis or subcutaneous fat. Defects should be",
"      <strong>",
"       under",
"      </strong>",
"      corrected at the time of treatment. (See",
"      <a class=\"local\" href=\"#H44882103\">",
"       'Poly-L-lactic acid (Sculptra&reg;)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subcutaneous papules are a common adverse effect of treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/21/13651?source=see_link\">",
"       poly-L-lactic acid",
"      </a>",
"      . In addition, treatment is not recommended for patients with a history of keloidal or hypertrophic scarring. (See",
"      <a class=\"local\" href=\"#H800623\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/1\">",
"      Beasley KL, Weiss MA, Weiss RA. Hyaluronic acid fillers: a comprehensive review. Facial Plast Surg 2009; 25:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/2\">",
"      Bray D, Hopkins C, Roberts DN. A review of dermal fillers in facial plastic surgery. Curr Opin Otolaryngol Head Neck Surg 2010; 18:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/3\">",
"      Hanke CW, Rohrich RJ, Busso M, et al. Facial Soft-Tissue Fillers conference: Assessing the State of the Science. J Am Acad Dermatol 2011; 64:S66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/4\">",
"      Duranti F, Salti G, Bovani B, et al. Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. Dermatol Surg 1998; 24:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/5\">",
"      Tezel A, Fredrickson GH. The science of hyaluronic acid dermal fillers. J Cosmet Laser Ther 2008; 10:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/6\">",
"      Kablik J, Monheit GD, Yu L, et al. Comparative physical properties of hyaluronic acid dermal fillers. Dermatol Surg 2009; 35 Suppl 1:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/7\">",
"      Pinsky MA, Thomas JA, Murphy DK, et al. Juv&eacute;derm injectable gel: a multicenter, double-blind, randomized study of safety and effectiveness. Aesthet Surg J 2008; 28:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/8\">",
"      Wang F, Garza LA, Kang S, et al. In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin. Arch Dermatol 2007; 143:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/9\">",
"      Varani J, Schuger L, Dame MK, et al. Reduced fibroblast interaction with intact collagen as a mechanism for depressed collagen synthesis in photodamaged skin. J Invest Dermatol 2004; 122:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/10\">",
"      Lambert CA, Colige AC, Lapi&egrave;re CM, Nusgens BV. Coordinated regulation of procollagens I and III and their post-translational enzymes by dissipation of mechanical tension in human dermal fibroblasts. Eur J Cell Biol 2001; 80:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/11\">",
"      Kessler D, Dethlefsen S, Haase I, et al. Fibroblasts in mechanically stressed collagen lattices assume a \"synthetic\" phenotype. J Biol Chem 2001; 276:36575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/12\">",
"      Kinney BM. Injecting Puragen Plus into the nasolabial folds: preliminary observations of FDA trial. Aesthet Surg J 2006; 26:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/13\">",
"      Onesti M, Toscani M, Curinga G, et al. Assessment of a new hyaluronic acid filler. double-blind, randomized, comparative study between Puragen and Captique in the treatment of nasolabial folds. In Vivo 2009; 23:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/14\">",
"      Matarasso SL, Carruthers JD, Jewell ML, Restylane Consensus Group. Consensus recommendations for soft-tissue augmentation with nonanimal stabilized hyaluronic acid (Restylane). Plast Reconstr Surg 2006; 117:3S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/15\">",
"      Carruthers J, Carruthers A, Maberley D. Deep resting glabellar rhytides respond to BTX-A and Hylan B. Dermatol Surg 2003; 29:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/16\">",
"      Carruthers J, Carruthers A. A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatol Surg 2003; 29:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/17\">",
"      Bosniak S, Cantisano-Zilkha M, Glavas IP. Nonanimal stabilized hyaluronic acid for lip augmentation and facial rhytid ablation. Arch Facial Plast Surg 2004; 6:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/18\">",
"      Carruthers J, Klein AW, Carruthers A, et al. Safety and efficacy of nonanimal stabilized hyaluronic acid for improvement of mouth corners. Dermatol Surg 2005; 31:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/19\">",
"      Narins RS, Brandt F, Leyden J, et al. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 2003; 29:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/20\">",
"      Carruthers A, Carey W, De Lorenzi C, et al. Randomized, double-blind comparison of the efficacy of two hyaluronic acid derivatives, restylane perlane and hylaform, in the treatment of nasolabial folds. Dermatol Surg 2005; 31:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/21\">",
"      Rao J, Chi GC, Goldman MP. Clinical comparison between two hyaluronic acid-derived fillers in the treatment of nasolabial folds: hylaform versus restylane. Dermatol Surg 2005; 31:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/22\">",
"      Baumann LS, Shamban AT, Lupo MP, et al. Comparison of smooth-gel hyaluronic acid dermal fillers with cross-linked bovine collagen: a multicenter, double-masked, randomized, within-subject study. Dermatol Surg 2007; 33 Suppl 2:S128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/23\">",
"      Narins RS, Dayan SH, Brandt FS, Baldwin EK. Persistence and improvement of nasolabial fold correction with nonanimal-stabilized hyaluronic acid 100,000 gel particles/mL filler on two retreatment schedules: results up to 18 months on two retreatment schedules. Dermatol Surg 2008; 34 Suppl 1:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/24\">",
"      Grimes PE, Thomas JA, Murphy DK. Safety and effectiveness of hyaluronic acid fillers in skin of color. J Cosmet Dermatol 2009; 8:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/25\">",
"      Schweiger ES, Riddle CC, Tonkovic-Capin V, Aires DJ. Successful treatment with injected hyaluronic acid in a patient with lip asymmetry after surgical correction of cleft lip. Dermatol Surg 2008; 34:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/26\">",
"      Bugge H, Negaard A, Skeie L, Bergersen B. Hyaluronic acid treatment of facial fat atrophy in HIV-positive patients. HIV Med 2007; 8:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/27\">",
"      Denton AB, Tsaparas Y. Injectable hyaluronic acid for the correction of HIV-associated facial lipoatrophy. Otolaryngol Head Neck Surg 2007; 136:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/28\">",
"      Bechara FG, Gambichler T, Brockmeyer NH, et al. Hyaluronic acid new formulation: experience in HIV-associated facial lipoatrophy. Dermatology 2008; 217:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/29\">",
"      DeLorenzi C, Weinberg M, Solish N, Swift A. The long-term efficacy and safety of a subcutaneously injected large-particle stabilized hyaluronic acid-based gel of nonanimal origin in esthetic facial contouring. Dermatol Surg 2009; 35 Suppl 1:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/30\">",
"      Skeie L, Bugge H, Negaard A, Bergersen BM. Large particle hyaluronic acid for the treatment of facial lipoatrophy in HIV-positive patients: 3-year follow-up study. HIV Med 2010; 11:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/31\">",
"      Lindqvist C, Tveten S, Bondevik BE, Fagrell D. A randomized, evaluator-blind, multicenter comparison of the efficacy and tolerability of Perlane versus Zyplast in the correction of nasolabial folds. Plast Reconstr Surg 2005; 115:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/32\">",
"      Lupo MP, Smith SR, Thomas JA, et al. Effectiveness of Juv&eacute;derm Ultra Plus dermal filler in the treatment of severe nasolabial folds. Plast Reconstr Surg 2008; 121:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/33\">",
"      Moers-Carpi M, Vogt S, Santos BM, et al. A multicenter, randomized trial comparing calcium hydroxylapatite to two hyaluronic acids for treatment of nasolabial folds. Dermatol Surg 2007; 33 Suppl 2:S144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/34\">",
"      Moers-Carpi MM, Tufet JO. Calcium hydroxylapatite versus nonanimal stabilized hyaluronic acid for the correction of nasolabial folds: a 12-month, multicenter, prospective, randomized, controlled, split-face trial. Dermatol Surg 2008; 34:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/35\">",
"      Levy PM, De Boulle K, Raspaldo H. Comparison of injection comfort of a new category of cohesive hyaluronic acid filler with preincorporated lidocaine and a hyaluronic acid filler alone. Dermatol Surg 2009; 35 Suppl 1:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/36\">",
"      Levy PM, De Boulle K, Raspaldo H. A split-face comparison of a new hyaluronic acid facial filler containing pre-incorporated lidocaine versus a standard hyaluronic acid facial filler in the treatment of naso-labial folds. J Cosmet Laser Ther 2009; 11:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/37\">",
"      Weinkle SH, Bank DE, Boyd CM, et al. A multi-center, double-blind, randomized controlled study of the safety and effectiveness of Juv&eacute;derm injectable gel with and without lidocaine. J Cosmet Dermatol 2009; 8:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/38\">",
"      Raspaldo H, De Boulle K, Levy PM. Longevity of effects of hyaluronic acid plus lidocaine facial filler. J Cosmet Dermatol 2010; 9:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/39\">",
"      Brandt F, Bank D, Cross SL, Weiss R. A lidocaine-containing formulation of large-gel particle hyaluronic acid alleviates pain. Dermatol Surg 2010; 36 Suppl 3:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/40\">",
"      Lupo MP, Swetman G, Waller W. The effect of lidocaine when mixed with large gel particle hyaluronic acid filler tolerability and longevity: a six-month trial. J Drugs Dermatol 2010; 9:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/41\">",
"      Monheit GD, Campbell RM, Neugent H, et al. Reduced pain with use of proprietary hyaluronic acid with lidocaine for correction of nasolabial folds: a patient-blinded, prospective, randomized controlled trial. Dermatol Surg 2010; 36:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/42\">",
"      Patel MP, Talmor M, Nolan WB. Botox and collagen for glabellar furrows: advantages of combination therapy. Ann Plast Surg 2004; 52:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/43\">",
"      Prager W, Steinkraus V. A prospective, rater-blind, randomized comparison of the effectiveness and tolerability of Belotero &reg; Basic versus Restylane &reg; for correction of nasolabial folds. Eur J Dermatol 2010; 20:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/44\">",
"      Glogau RG, Kane MA. Effect of injection techniques on the rate of local adverse events in patients implanted with nonanimal hyaluronic acid gel dermal fillers. Dermatol Surg 2008; 34 Suppl 1:S105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/45\">",
"      Kono T, Kinney BM, Groff WF, et al. Randomized, evaluator-blind, split-face comparison study of single cross-linked versus double cross-linked hyaluronic acid in the treatment of glabellar lines. Dermatol Surg 2008; 34 Suppl 1:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/46\">",
"      Arlette JP, Trotter MJ. Anatomic location of hyaluronic acid filler material injected into nasolabial fold: a histologic study. Dermatol Surg 2008; 34 Suppl 1:S56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/47\">",
"      Greco TM, Elenitsas R. Localization and histological characterization of injected hyaluronic acid in excised nasolabial fold tissue. J Drugs Dermatol 2010; 9:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/48\">",
"      Jordan DR. Soft-tissue fillers for wrinkles, folds and volume augmentation. Can J Ophthalmol 2003; 38:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/49\">",
"      Requena L, Requena C, Christensen L, et al. Adverse reactions to injectable soft tissue fillers. J Am Acad Dermatol 2011; 64:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/50\">",
"      Hirsch RJ, Narurkar V, Carruthers J. Management of injected hyaluronic acid induced Tyndall effects. Lasers Surg Med 2006; 38:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/51\">",
"      Douse-Dean T, Jacob CI. Fast and easy treatment for reduction of the Tyndall effect secondary to cosmetic use of hyaluronic acid. J Drugs Dermatol 2008; 7:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/52\">",
"      Sclafani AP, Fagien S. Treatment of injectable soft tissue filler complications. Dermatol Surg 2009; 35 Suppl 2:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/53\">",
"      Lupton JR, Alster TS. Cutaneous hypersensitivity reaction to injectable hyaluronic acid gel. Dermatol Surg 2000; 26:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/54\">",
"      Lowe NJ, Maxwell CA, Lowe P, et al. Hyaluronic acid skin fillers: adverse reactions and skin testing. J Am Acad Dermatol 2001; 45:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/55\">",
"      Leonhardt JM, Lawrence N, Narins RS. Angioedema acute hypersensitivity reaction to injectable hyaluronic acid. Dermatol Surg 2005; 31:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/56\">",
"      Matarasso SL, Herwick R. Hypersensitivity reaction to nonanimal stabilized hyaluronic acid. J Am Acad Dermatol 2006; 55:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/57\">",
"      Patel VJ, Bruck MC, Katz BE. Hypersensitivity reaction to hyaluronic acid with negative skin testing. Plast Reconstr Surg 2006; 117:92e.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/58\">",
"      Arron ST, Neuhaus IM. Persistent delayed-type hypersensitivity reaction to injectable non-animal-stabilized hyaluronic acid. J Cosmet Dermatol 2007; 6:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/59\">",
"      Bisaccia E, Lugo A, Torres O, et al. Persistent inflammatory reaction to hyaluronic acid gel: a case report. Cutis 2007; 79:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/60\">",
"      Andr&eacute; P. Evaluation of the safety of a non-animal stabilized hyaluronic acid (NASHA -- Q-Medical, Sweden) in European countries: a retrospective study from 1997 to 2001. J Eur Acad Dermatol Venereol 2004; 18:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/61\">",
"      Saylan Z. Facial fillers and their complications. Aesthet Surg J 2003; 23:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/62\">",
"      Fern&aacute;ndez-Ace&ntilde;ero MJ, Zamora E, Borbujo J. Granulomatous foreign body reaction against hyaluronic acid: report of a case after lip augmentation. Dermatol Surg 2003; 29:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/63\">",
"      H&ouml;nig JF, Brink U, Korabiowska M. Severe granulomatous allergic tissue reaction after hyaluronic acid injection in the treatment of facial lines and its surgical correction. J Craniofac Surg 2003; 14:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/64\">",
"      Jordan DR. Delayed inflammatory reaction to hyaluronic acid (Restylane). Ophthal Plast Reconstr Surg 2005; 21:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/65\">",
"      Edwards PC, Fantasia JE, Iovino R. Foreign body reaction to hyaluronic acid (Restylane): an adverse outcome of lip augmentation. J Oral Maxillofac Surg 2006; 64:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/66\">",
"      Ghislanzoni M, Bianchi F, Barbareschi M, Alessi E. Cutaneous granulomatous reaction to injectable hyaluronic acid gel. Br J Dermatol 2006; 154:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/67\">",
"      Al-Shraim M, Jaragh M, Geddie W. Granulomatous reaction to injectable hyaluronic acid (Restylane) diagnosed by fine needle biopsy. J Clin Pathol 2007; 60:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/68\">",
"      Bardazzi F, Ruffato A, Antonucci A, et al. Cutaneous granulomatous reaction to injectable hyaluronic acid gel: another case. J Dermatolog Treat 2007; 18:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/69\">",
"      Okada S, Okuyama R, Tagami H, Aiba S. Eosinophilic granulomatous reaction after intradermal injection of hyaluronic acid. Acta Derm Venereol 2008; 88:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/70\">",
"      Mamelak AJ, Katz TM, Goldberg LH, et al. Foreign body reaction to hyaluronic acid filler injection: in search of an etiology. Dermatol Surg 2009; 35 Suppl 2:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/71\">",
"      Sage RJ, Chaffins ML, Kouba DJ. Granulomatous foreign body reaction to hyaluronic acid: report of a case after melolabial fold augmentation and review of management. Dermatol Surg 2009; 35 Suppl 2:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/72\">",
"      Alsaad SM, Fabi SG, Goldman MP. Granulomatous reaction to hyaluronic acid: a case series and review of the literature. Dermatol Surg 2012; 38:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/73\">",
"      Schanz S, Schippert W, Ulmer A, et al. Arterial embolization caused by injection of hyaluronic acid (Restylane). Br J Dermatol 2002; 146:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/74\">",
"      Peter S, Mennel S. Retinal branch artery occlusion following injection of hyaluronic acid (Restylane). Clin Experiment Ophthalmol 2006; 34:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/75\">",
"      Hirsch RJ, Cohen JL, Carruthers JD. Successful management of an unusual presentation of impending necrosis following a hyaluronic acid injection embolus and a proposed algorithm for management with hyaluronidase. Dermatol Surg 2007; 33:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/76\">",
"      Inoue K, Sato K, Matsumoto D, et al. Arterial embolization and skin necrosis of the nasal ala following injection of dermal fillers. Plast Reconstr Surg 2008; 121:127e.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/77\">",
"      Burt B, Nakra T, Isaacs DK, Goldberg RA. Alar necrosis after facial injection of hyaluronic Acid. Plast Reconstr Surg 2010; 125:199e.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/78\">",
"      Bachmann F, Erdmann R, Hartmann V, et al. The spectrum of adverse reactions after treatment with injectable fillers in the glabellar region: results from the Injectable Filler Safety Study. Dermatol Surg 2009; 35 Suppl 2:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/79\">",
"      D'Acunto C, Pazzaglia M, Raone B, et al. Xanthelasma palpebrarum: a new adverse reaction to intradermal fillers? Br J Dermatol 2013; 168:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/80\">",
"      Brody HJ. Use of hyaluronidase in the treatment of granulomatous hyaluronic acid reactions or unwanted hyaluronic acid misplacement. Dermatol Surg 2005; 31:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/81\">",
"      Soparkar CN, Patrinely JR, Tschen J. Erasing restylane. Ophthal Plast Reconstr Surg 2004; 20:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/82\">",
"      Goldberg RA, Fiaschetti D. Filling the periorbital hollows with hyaluronic acid gel: initial experience with 244 injections. Ophthal Plast Reconstr Surg 2006; 22:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/83\">",
"      Hirsch RJ, Brody HJ, Carruthers JD. Hyaluronidase in the office: a necessity for every dermasurgeon that injects hyaluronic acid. J Cosmet Laser Ther 2007; 9:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/84\">",
"      Pierre A, Levy PM. Hyaluronidase offers an efficacious treatment for inaesthetic hyaluronic acid overcorrection. J Cosmet Dermatol 2007; 6:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/85\">",
"      Vartanian AJ, Frankel AS, Rubin MG. Injected hyaluronidase reduces restylane-mediated cutaneous augmentation. Arch Facial Plast Surg 2005; 7:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/86\">",
"      Lee A, Grummer SE, Kriegel D, Marmur E. Hyaluronidase. Dermatol Surg 2010; 36:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/87\">",
"      Andre P, Fl&eacute;chet ML. Angioedema after ovine hyaluronidase injection for treating hyaluronic acid overcorrection. J Cosmet Dermatol 2008; 7:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/88\">",
"      Menon H, Thomas M, D'silva J. Low dose of Hyaluronidase to treat over correction by HA filler--a case report. J Plast Reconstr Aesthet Surg 2010; 63:e416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/89\">",
"      Knapp TR, Kaplan EN, Daniels JR. Injectable collagen for soft tissue augmentation. Plast Reconstr Surg 1977; 60:398.",
"     </a>",
"    </li>",
"    <li>",
"     Sengelmann RD, Tull S, Pollack SV. Soft-tissue augmentation. In: Surgery of the Skin: Procedural Dermatology, Robinson JK, Hanke CW, Sengelmann RD, et al..  (Eds), Elsevier, Inc., Spain 2005. p.437.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/91\">",
"      Matarasso SL. The use of injectable collagens for aesthetic rejuvenation. Semin Cutan Med Surg 2006; 25:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/92\">",
"      Narins RS, Brandt FS, Lorenc ZP, et al. A randomized, multicenter study of the safety and efficacy of Dermicol-P35 and non-animal-stabilized hyaluronic acid gel for the correction of nasolabial folds. Dermatol Surg 2007; 33 Suppl 2:S213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/93\">",
"      Watson W, Kaye RL, Klein A, Stegman S. Injectable collagen: a clinical overview. Cutis 1983; 31:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/94\">",
"      Smith S, Busso M, McClaren M, Bass LS. A randomized, bilateral, prospective comparison of calcium hydroxylapatite microspheres versus human-based collagen for the correction of nasolabial folds. Dermatol Surg 2007; 33 Suppl 2:S112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/95\">",
"      Cooperman LS, Mackinnon V, Bechler G, Pharriss BB. Injectable collagen: a six-year clinical investigation. Aesthetic Plast Surg 1985; 9:145.",
"     </a>",
"    </li>",
"    <li>",
"     Zyderm&reg; collagen implant [package insert]. Fremont, CA: McGhan Medical Corporation; 2000.",
"    </li>",
"    <li>",
"     Zyplast&reg; collagen implant [package insert]. Fremont, CA: McGhan Medical Corporation; 2000.",
"    </li>",
"    <li>",
"     CosmoDerm [package insert]. Irvine, CA: Allergan, Inc; 2007.",
"    </li>",
"    <li>",
"     CosmoPlast [package insert]. Irvine, CA: Allergan, Inc; 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/100\">",
"      Hanke CW, Higley HR, Jolivette DM, et al. Abscess formation and local necrosis after treatment with Zyderm or Zyplast collagen implant. J Am Acad Dermatol 1991; 25:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/101\">",
"      Badalamente MA, Hurst LC. Enzyme injection as nonsurgical treatment of Dupuytren's disease. J Hand Surg Am 2000; 25:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/102\">",
"      Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med 2009; 361:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/103\">",
"      Watt AJ, Curtin CM, Hentz VR. Collagenase injection as nonsurgical treatment of Dupuytren's disease: 8-year follow-up. J Hand Surg Am 2010; 35:534.",
"     </a>",
"    </li>",
"    <li>",
"     Radiesse&reg; injectable implant: Instructions for use. Franksville, WI: BioForm Medical, Inc; 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/105\">",
"      Marmur ES, Phelps R, Goldberg DJ. Clinical, histologic and electron microscopic findings after injection of a calcium hydroxylapatite filler. J Cosmet Laser Ther 2004; 6:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/106\">",
"      Graivier MH, Bass LS, Busso M, et al. Calcium hydroxylapatite (Radiesse) for correction of the mid- and lower face: consensus recommendations. Plast Reconstr Surg 2007; 120:55S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/107\">",
"      Tzikas TL. A 52-month summary of results using calcium hydroxylapatite for facial soft tissue augmentation. Dermatol Surg 2008; 34 Suppl 1:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/108\">",
"      Tzikas TL. Evaluation of the Radiance FN soft tissue filler for facial soft tissue augmentation. Arch Facial Plast Surg 2004; 6:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/109\">",
"      Cuevas S, Rivas MP, Amini S, Weiss E. Radiesse for aesthetic soft tissue augmentation. Am J Cosmet Surg 2006; 23:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/110\">",
"      Jacovella PF, Peiretti CB, Cunille D, et al. Long-lasting results with hydroxylapatite (Radiesse) facial filler. Plast Reconstr Surg 2006; 118:15S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/111\">",
"      Jansen DA, Graivier MH. Evaluation of a calcium hydroxylapatite-based implant (Radiesse) for facial soft-tissue augmentation. Plast Reconstr Surg 2006; 118:22S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/112\">",
"      Alam M, Yoo SS. Technique for calcium hydroxylapatite injection for correction of nasolabial fold depressions. J Am Acad Dermatol 2007; 56:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/113\">",
"      Sadick NS, Katz BE, Roy D. A multicenter, 47-month study of safety and efficacy of calcium hydroxylapatite for soft tissue augmentation of nasolabial folds and other areas of the face. Dermatol Surg 2007; 33 Suppl 2:S122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/114\">",
"      Sklar JA, White SM. Radiance FN: a new soft tissue filler. Dermatol Surg 2004; 30:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/115\">",
"      Comite SL, Liu JF, Balasubramanian S, Christian MA. Treatment of HIV-associated facial lipoatrophy with Radiance FN (Radiesse). Dermatol Online J 2004; 10:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/116\">",
"      Roth JS. Restorative approaches for HIV-associated lipoatrophy. PRS Notebook 2005; 10:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/117\">",
"      Busso M, Karlsberg PL. Cheek augmentation and rejuvenation using injectable calcium hydroxylapatite (Radiesse). Cosmet Dermatol 2006; 19:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/118\">",
"      Silvers SL, Eviatar JA, Echavez MI, Pappas AL. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg 2006; 118:34S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/119\">",
"      Carruthers A, Carruthers J. Evaluation of injectable calcium hydroxylapatite for the treatment of facial lipoatrophy associated with human immunodeficiency virus. Dermatol Surg 2008; 34:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/120\">",
"      Marmur E, Green L, Busso M. Controlled, randomized study of pain levels in subjects treated with calcium hydroxylapatite premixed with lidocaine for correction of nasolabial folds. Dermatol Surg 2010; 36:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/121\">",
"      Bass LS, Smith S, Busso M, McClaren M. Calcium hydroxylapatite (Radiesse) for treatment of nasolabial folds: long-term safety and efficacy results. Aesthet Surg J 2010; 30:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/122\">",
"      Sankar V, McGuff HS. Foreign body reaction to calcium hydroxylapatite after lip augmentation. J Am Dent Assoc 2007; 138:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/123\">",
"      Reddy KK, Brauer JA, Anolik R, et al. Calcium hydroxylapatite nodule resolution after fractional carbon dioxide laser therapy. Arch Dermatol 2012; 148:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/124\">",
"      Carruthers A, Liebeskind M, Carruthers J, Forster BB. Radiographic and computed tomographic studies of calcium hydroxylapatite for treatment of HIV-associated facial lipoatrophy and correction of nasolabial folds. Dermatol Surg 2008; 34 Suppl 1:S78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/125\">",
"      Valiyaparambil J, Rengasamy K, Mallya SM. An unusual soft tissue radiopacity--radiographic appearance of a dermal filler. Br Dent J 2009; 207:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/126\">",
"      Alam M, Havey J, Pace N, et al. Large-particle calcium hydroxylapatite injection for correction of facial wrinkles and depressions. J Am Acad Dermatol 2011; 65:92.",
"     </a>",
"    </li>",
"    <li>",
"     Sculptra&reg; (injectable poly-L-lactic acid) Prescribing Information. Bridgewater, NJ: Dermik Laboratories; 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/128\">",
"      Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003; 17:2471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/129\">",
"      Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004; 5:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/130\">",
"      Mest DR, Humble G. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience. Dermatol Surg 2006; 32:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/131\">",
"      Borelli C, Kunte C, Weisenseel P, et al. Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients. Skin Pharmacol Physiol 2005; 18:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/132\">",
"      Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol 2005; 52:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/133\">",
"      Bodokh I, Simonet P. [Polylactic acid injections (Newfill) in the treatment of facial lipodystrophy in HIV-positive patients]. Ann Dermatol Venereol 2006; 133:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/134\">",
"      Cattelan AM, Bauer U, Trevenzoli M, et al. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy. Arch Dermatol 2006; 142:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/135\">",
"      Moyle GJ, Brown S, Lysakova L, Barton SE. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med 2006; 7:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/136\">",
"      Carey DL, Baker D, Rogers GD, et al. A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy. J Acquir Immune Defic Syndr 2007; 46:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/137\">",
"      Hanke CW, Redbord KP. Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging. J Drugs Dermatol 2007; 6:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/138\">",
"      Levy RM, Redbord KP, Hanke CW. Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study. J Am Acad Dermatol 2008; 59:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/139\">",
"      Narciso P, Bucciardini R, Tozzi V, et al. Immediate versus delayed surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy: a randomized open-label study. AIDS Res Hum Retroviruses 2009; 25:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/140\">",
"      El-Beyrouty C, Huang V, Darnold CJ, Clay PG. Poly-L-lactic acid for facial lipoatrophy in HIV. Ann Pharmacother 2006; 40:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/141\">",
"      Mest DR, Humble GM. Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study. Dermatol Surg 2009; 35 Suppl 1:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/142\">",
"      Beer K. A single-center, open-label study on the use of injectable poly-L-lactic acid for the treatment of moderate to severe scarring from acne or varicella. Dermatol Surg 2007; 33 Suppl 2:S159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/143\">",
"      Onesti MG, Troccola A, Scuderi N. Volumetric correction using poly-L-lactic acid in facial asymmetry: Parry Romberg syndrome and scleroderma. Dermatol Surg 2009; 35:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/144\">",
"      Sadick NS, Palmisano L. Case study involving use of injectable poly-L-lactic acid (PLLA) for acne scars. J Dermatolog Treat 2009; 20:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/145\">",
"      Sadove R. Injectable poly-L: -lactic acid: a novel sculpting agent for the treatment of dermal fat atrophy after severe acne. Aesthetic Plast Surg 2009; 33:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/146\">",
"      Vleggaar D, Bauer U. Facial enhancement and the European experience with Sculptra (poly-l-lactic acid). J Drugs Dermatol 2004; 3:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/147\">",
"      Woerle B, Hanke CW, Sattler G. Poly-L-lactic acid: a temporary filler for soft tissue augmentation. J Drugs Dermatol 2004; 3:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/148\">",
"      Vleggaar D. Facial volumetric correction with injectable poly-L-lactic acid. Dermatol Surg 2005; 31:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/149\">",
"      Salles AG, Lotierzo PH, Gimenez R, et al. Evaluation of the poly-L-lactic acid implant for treatment of the nasolabial fold: 3-year follow-up evaluation. Aesthetic Plast Surg 2008; 32:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/150\">",
"      Lowe NJ, Maxwell CA, Lowe P, et al. Injectable poly-l-lactic acid: 3 years of aesthetic experience. Dermatol Surg 2009; 35 Suppl 1:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/151\">",
"      Narins RS, Baumann L, Brandt FS, et al. A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. J Am Acad Dermatol 2010; 62:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/152\">",
"      Palm MD, Woodhall KE, Butterwick KJ, Goldman MP. Cosmetic use of poly-l-lactic acid: a retrospective study of 130 patients. Dermatol Surg 2010; 36:161.",
"     </a>",
"    </li>",
"    <li>",
"     Sculptra (injectable poly-L-lactic acid) Prescribing information. file://products.sanofi-aventis.us/sculptra/sculptra.html (Accessed on May 13, 2011).",
"    </li>",
"    <li>",
"     Sculptra Aesthetic (injectable poly-L-lactic acid) Prescribing information.file://products.sanofi-aventis.us/sculptra_aesthetic/sculptra_aesthetic.html (Accessed on May 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/155\">",
"      Reszko AE, Sadick NS, Magro CM, Farber J. Late-onset subcutaneous nodules after poly-L-lactic acid injection. Dermatol Surg 2009; 35 Suppl 1:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/156\">",
"      Barton SE, Engelhard P, Conant M. Poly-L-lactic acid for treating HIV-associated facial lipoatrophy: a review of the clinical studies. Int J STD AIDS 2006; 17:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/157\">",
"      Narins RS. Minimizing adverse events associated with poly-L-lactic acid injection. Dermatol Surg 2008; 34 Suppl 1:S100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/158\">",
"      Wildemore JK, Jones DH. Persistent granulomatous inflammatory response induced by injectable poly-L-lactic acid for HIV lipoatrophy. Dermatol Surg 2006; 32:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/159\">",
"      Goldan O, Garbov-Nardini G, Regev E, et al. Late-onset infections and granuloma formation after facial polylactic acid (New-Fill) injections in women who are heavy smokers. Plast Reconstr Surg 2008; 121:336e.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/160\">",
"      Alijotas-Reig J, Garcia-Gimenez V, Vilardell-Tarres M. Late-onset immune-mediated adverse effects after poly-L-lactic acid injection in non-HIV patients: clinical findings and long-term follow-up. Dermatology 2009; 219:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/161\">",
"      Sclafani AP. Applications of platelet-rich fibrin matrix in facial plastic surgery. Facial Plast Surg 2009; 25:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/23/23930/abstract/162\">",
"      Sclafani AP. Platelet-rich fibrin matrix for improvement of deep nasolabial folds. J Cosmet Dermatol 2010; 9:66.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16399 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-D70169F40B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_23_23930=[""].join("\n");
var outline_f23_23_23930=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33951432\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44881949\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44881956\">",
"      HYALURONIC ACID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44887349\">",
"      Product characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44881970\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44881984\">",
"      Formulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44881991\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44887654\">",
"      - Versus bovine collagen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44887647\">",
"      - Versus calcium hydroxylapatite",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1866561\">",
"      - With lidocaine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1117199\">",
"      - With botulinum toxin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44887668\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44881998\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1117242\">",
"      Reversal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44882012\">",
"      COLLAGEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33951301\">",
"      Formulations and use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44882019\">",
"      - Bovine collagen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44882026\">",
"      - Human collagen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44882033\">",
"      - Autologous collagen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44882040\">",
"      - Porcine collagen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44882047\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44882054\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44882061\">",
"      Reversal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44882068\">",
"      CALCIUM HYDROXYLAPATITE (RADIESSE&reg;)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33951425\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44882082\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33951353\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44882089\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2827103\">",
"      Large particle calcium hydroxylapatite",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44882103\">",
"      POLY-L-LACTIC ACID (SCULPTRA&reg;)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44882110\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H799852\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H800758\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H800623\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H801577\">",
"      PLATELET-RICH FIBRIN MATRIX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33951432\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/16399\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16399|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/19/23858\" title=\"figure 1\">",
"      Placement of injectable soft tissue fillers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16399|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/45/23261\" title=\"table 1\">",
"      Biodegradeable soft tissue fillers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/36/41548\" title=\"table 2\">",
"      Properties of hyaluronic acid fillers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27049?source=related_link\">",
"      Injectable soft tissue fillers: Overview of clinical use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26024?source=related_link\">",
"      Injectable soft tissue fillers: Permanent agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22778?source=related_link\">",
"      Overview of botulinum toxin for cosmetic indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44409?source=related_link\">",
"      Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_23_23931="Classification progestins in combined OC pills";
var content_f23_23_23931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F87416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F87416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of progestins used in combined oral contraceptive pills",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        First generation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Norethindrone acetate",
"         </li>",
"         <li>",
"          Ethynodiol diacetate",
"         </li>",
"         <li>",
"          Lynestrenol",
"         </li>",
"         <li>",
"          Norethynodrel",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Second generation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          dl-Norgestrel",
"         </li>",
"         <li>",
"          Levonorgestrel",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Third generation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Desogestrel",
"         </li>",
"         <li>",
"          Gestodene",
"         </li>",
"         <li>",
"          Norgestimate",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Unclassified",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Drospirenone",
"         </li>",
"         <li>",
"          Cyproterone acetate",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Reust CE, Espinoza SA, Ruplinger J, Swofford S. What is the approach to intermenstrual bleeding in a woman taking a combined oral contraceptive? Evidence-Based Practice 2012; 15:29. Copyright &copy; 2013 Family Physicians Inquiries Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_23_23931=[""].join("\n");
var outline_f23_23_23931=null;
var title_f23_23_23932="Characteristics of support surfaces";
var content_f23_23_23932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of support surfaces",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Support surface",
"       </td>",
"       <td class=\"subtitle1\">",
"        Increased support area",
"       </td>",
"       <td class=\"subtitle1\">",
"        Low moisture retention",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reduced heat accumulation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Shear reduction",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pressure reduction",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dynamic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cost",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Standard hospital mattress",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foam",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Static flotation (air or water)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alternating air (dynamic)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low air loss",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes with cover",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Air fluidized (high air loss)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Treatment of pressure ulcers. Clinical Practice Guideline Number 15, publication no. 95-0652. The Agency for Health Care Policy and Research (AHCPR), Rockville, MD 1994.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_23_23932=[""].join("\n");
var outline_f23_23_23932=null;
var title_f23_23_23933="ACC AHA HRS AV block";
var content_f23_23_23933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA/HRS guideline summary: Indications for permanent pacing in acquired atrioventricular (AV) block in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement that permanent pacing is indicated in adults with (acquired AV block) in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       &bull; Third-degree and advanced second-degree AV block at any anatomic level:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       1. Associated with bradycardia with symptoms (including heart failure) or ventricular arrhythmias presumed to be due to AV block. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       2. Associated with arrhythmias and other medical conditions that require drug therapy that results in symptomatic bradycardia. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       3. In awake, symptom-free patients in sinus rhythm, with documented periods of asystole &ge;3.0 seconds or any escape rate &lt;40 bpm, or with an escape rhythm that is below the AV node. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       4. In awake, symptom-free patients with AF and bradycardia with 1 or more pauses of at least 5 seconds or longer. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       5. After catheter ablation of the AV junction. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       6. Associated with postoperative AV block that is not expected to resolve after cardiac surgery. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       7. Associated with neuromuscular diseases with AV block, such as myotonic muscular dystrophy, Kearns-Sayre syndrome, Erb dystrophy (limb-girdle muscular dystrophy), and peroneal muscular atrophy, with or without symptoms. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Second-degree AV block with associated symptomatic bradycardia regardless of type or site of block. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Asymptomatic persistent third-degree AV block at any anatomic site with average awake ventricular rates of 40 bpm or faster if cardiomegaly or LV dysfunction is present or if the site of block is below the AV node. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Second- or third-degree AV block during exercise in the absence of myocardial ischemia. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIa - The weight of evidence or opinion is in favor of the usefulness of permanent pacing in adults with (acquired AV block) in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Persistent third-degree AV block with an escape rate &gt;40 bpm in asymptomatic adult patients without cardiomegaly. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Asymptomatic second-degree AV block at intra- or infra-His levels found at electrophysiological study. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; First- or second-degree AV block with symptoms similar to those of pacemaker syndrome or hemodynamic compromise. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Asymptomatic type II second-degree AV block with a narrow QRS. When type II second-degree AV block occurs with a wide QRS, including isolated right bundle-branch block, pacing becomes a Class I recommendation. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIb - The weight of evidence or opinion is less well established for the usefulness of permanent pacing in adults with acquired AV block in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Neuromuscular diseases such as myotonic muscular dystrophy, Erb dystrophy (limb-girdle muscular dystrophy), and peroneal muscular atrophy with any degree of AV block (including first-degree AV block), with or without symptoms, because there may be unpredictable progression of AV conduction disease. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; AV block in the setting of drug use and/or drug toxicity when the block is expected to recur even after the drug is withdrawn. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class III - There is evidence and/or general agreement that permanent pacing in adults with acquired AV block is not useful in in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Asymptomatic first-degree AV block. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Asymptomatic type I second-degree AV block at the supra-His (AV node) level or that which is not known to be intra- or infra-Hisian. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; AV block that is expected to resolve and is unlikely to recur (e.g., drug toxicity, Lyme disease, or transient increases in vagal tone or during hypoxia in sleep apnea syndrome in the absence of symptoms). (Level of Evidence: B)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_23_23933=[""].join("\n");
var outline_f23_23_23933=null;
var title_f23_23_23934="Drug reactions RUCAM";
var content_f23_23_23934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Method for causality assessment of adverse drug reactions (RUCAM) (CIOMS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Hepatocellular",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Cholestatic or mixed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Exposure",
"       </td>",
"       <td class=\"subtitle2\">",
"        Initial",
"       </td>",
"       <td class=\"subtitle2\">",
"        Subsequent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Points",
"       </td>",
"       <td class=\"subtitle2\">",
"        Initial",
"       </td>",
"       <td class=\"subtitle2\">",
"        Subsequent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Time from drug start (days)",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         5-90",
"        </p>",
"        &lt;5 or &gt;90",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         1-15",
"        </p>",
"        &gt;15",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         +2",
"        </p>",
"        +1",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         5-90",
"        </p>",
"        &lt;5 or &gt;90",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         1-90",
"        </p>",
"        &gt;90",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         +2",
"        </p>",
"        +1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Time from drug stop (days)",
"       </td>",
"       <td class=\"centered\">",
"        &le;15",
"       </td>",
"       <td class=\"centered\">",
"        &le;15",
"       </td>",
"       <td class=\"centered\">",
"        +1",
"       </td>",
"       <td class=\"centered\">",
"        &le;30",
"       </td>",
"       <td class=\"centered\">",
"        &le;30",
"       </td>",
"       <td class=\"centered\">",
"        +1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"3\">",
"        Difference between peak ALT and ULN",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"3\">",
"        Difference between peak AP (or bilirubin) and ULN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Course after stopping drug",
"       </td>",
"       <td colspan=\"2\">",
"        Decrease &ge;50 percent in 8 days",
"       </td>",
"       <td class=\"centered\">",
"        +3",
"       </td>",
"       <td colspan=\"2\">",
"        Decrease &ge;50 percent in &lt;180 days",
"       </td>",
"       <td class=\"centered\">",
"        +2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Decrease &ge;50 percent in 30 days",
"       </td>",
"       <td class=\"centered\">",
"        +2",
"       </td>",
"       <td colspan=\"2\">",
"        Decrease &lt;50 percent in &lt;180 days",
"       </td>",
"       <td class=\"centered\">",
"        +1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Decrease &ge;50 percent in &gt;30 days",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td colspan=\"2\">",
"        Persistence or increase or no information",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Decrease &lt;50 percent in &gt;30 days",
"       </td>",
"       <td class=\"centered\">",
"        -2",
"       </td>",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Risk factor",
"       </td>",
"       <td colspan=\"2\">",
"        Ethanol: yes",
"       </td>",
"       <td class=\"centered\">",
"        +1",
"       </td>",
"       <td colspan=\"2\">",
"        Ethanol or pregnancy: yes",
"       </td>",
"       <td class=\"centered\">",
"        +1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Ethanol: no",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td colspan=\"2\">",
"        Ethanol or pregnancy: no",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Age",
"       </td>",
"       <td colspan=\"2\">",
"        &ge;55 years",
"       </td>",
"       <td class=\"centered\">",
"        +1",
"       </td>",
"       <td colspan=\"2\">",
"        &ge;55 years",
"       </td>",
"       <td class=\"centered\">",
"        +1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        &lt;55 years",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td colspan=\"2\">",
"        &lt;55 years",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Other drugs",
"       </td>",
"       <td colspan=\"2\">",
"        None or no information",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td colspan=\"2\">",
"        None or no information",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Drug with suggestive timing",
"       </td>",
"       <td class=\"centered\">",
"        -1",
"       </td>",
"       <td colspan=\"2\">",
"        Drug with suggestive timing",
"       </td>",
"       <td class=\"centered\">",
"        -1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Known hepatotoxin with suggestive timing",
"       </td>",
"       <td class=\"centered\">",
"        -2",
"       </td>",
"       <td colspan=\"2\">",
"        Known hepatotoxin with suggestive timing",
"       </td>",
"       <td class=\"centered\">",
"        -2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Drug with other evidence for a role (eg, + rechallenge)",
"       </td>",
"       <td class=\"centered\">",
"        -3",
"       </td>",
"       <td colspan=\"2\">",
"        Drug with other evidence for a role (eg, + rechallenge)",
"       </td>",
"       <td class=\"centered\">",
"        -3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"5\">",
"        Competing causes",
"       </td>",
"       <td colspan=\"2\">",
"        All group I* &amp; II",
"        <sup>",
"         &bull;",
"        </sup>",
"        ruled out",
"       </td>",
"       <td class=\"centered\">",
"        +2",
"       </td>",
"       <td colspan=\"2\">",
"        All group I* &amp; II",
"        <sup>",
"         &bull;",
"        </sup>",
"        ruled out",
"       </td>",
"       <td class=\"centered\">",
"        +2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        All of group I ruled out",
"       </td>",
"       <td class=\"centered\">",
"        +1",
"       </td>",
"       <td colspan=\"2\">",
"        All of group I ruled out",
"       </td>",
"       <td class=\"centered\">",
"        +1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        4-5 of group I ruled out",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td colspan=\"2\">",
"        4-5 of group I ruled out",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        &lt;4 of group I ruled out",
"       </td>",
"       <td class=\"centered\">",
"        -2",
"       </td>",
"       <td colspan=\"2\">",
"        &lt;4 of group I ruled out",
"       </td>",
"       <td class=\"centered\">",
"        -2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Non-drug cause highly probable",
"       </td>",
"       <td class=\"centered\">",
"        -3",
"       </td>",
"       <td colspan=\"2\">",
"        Non-drug cause highly probable",
"       </td>",
"       <td class=\"centered\">",
"        -3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Previous information",
"       </td>",
"       <td colspan=\"2\">",
"        Reaction in product label",
"       </td>",
"       <td class=\"centered\">",
"        +2",
"       </td>",
"       <td colspan=\"2\">",
"        Reaction in product label",
"       </td>",
"       <td class=\"centered\">",
"        +2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Reaction published; no label",
"       </td>",
"       <td class=\"centered\">",
"        +1",
"       </td>",
"       <td colspan=\"2\">",
"        Reaction published; no label",
"       </td>",
"       <td class=\"centered\">",
"        +1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Reaction unknown",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td colspan=\"2\">",
"        Reaction unknown",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Rechallenge",
"       </td>",
"       <td colspan=\"2\">",
"        Positive",
"       </td>",
"       <td class=\"centered\">",
"        +3",
"       </td>",
"       <td colspan=\"2\">",
"        Positive",
"       </td>",
"       <td class=\"centered\">",
"        +3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Compatible",
"       </td>",
"       <td class=\"centered\">",
"        +1",
"       </td>",
"       <td colspan=\"2\">",
"        Compatible",
"       </td>",
"       <td class=\"centered\">",
"        +1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Negative",
"       </td>",
"       <td class=\"centered\">",
"        -1",
"       </td>",
"       <td colspan=\"2\">",
"        Negative",
"       </td>",
"       <td class=\"centered\">",
"        -1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Not done or not interpretable",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td colspan=\"2\">",
"        Not done or not interpretable",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    If incompatible, then case \"unrelated\".",
"    <br/>",
"    If information not available, then case \"insufficiently documented\".",
"    <br/>",
"    <strong>",
"     Scoring:",
"    </strong>",
"    <br/>",
"    &le;0: Relationship with the drug excluded",
"    <br/>",
"    1-2: Unlikely",
"    <br/>",
"    3-5: Possible",
"    <br/>",
"    6-8: Probable",
"    <br/>",
"    &gt;8: Highly probable",
"    <div class=\"footnotes\">",
"     RUCAM: Roussel Uclaf Causality Assessment Method; ALT: alanine aminotransferase; ULN: upper limit of normal; HAV: hepatitis A virus; HBV: hepatitis B virus; HCV: hepatitis C virus; CMV: cytomegalovirus; EBV: Epstein-Barr virus.",
"     <br>",
"      * Group I: HAV, HBV, HCV (acute), biliary obstruction, alcoholism, recent hypotension (shock liver).",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Group II: CMV, EBV, herpes virus infection.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Hayashi PH. Causality assessment in drug-induced liver injury. Semin Liver Dis 2009; 29:348. Copyright &copy; 2009 Thieme Publishers.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_23_23934=[""].join("\n");
var outline_f23_23_23934=null;
var title_f23_23_23935="Approach to the child with diplopia";
var content_f23_23_23935=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 586px\">",
"   <div class=\"ttl\">",
"    Approach to the child with diplopia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 566px; height: 763px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CN: cranial nerve; IIH: idiopathic intracranial hypertension.",
"     <br>",
"      * See table, \"Etiology third nerve palsy\".",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       See table, \"Etiology fourth nerve palsy\".",
"       <br>",
"        &Delta; See table, \"Etiology sixth nerve palsy\".",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         Diplopia from causes other than CN VI palsy may occur with IIH.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_23_23935=[""].join("\n");
var outline_f23_23_23935=null;
